

Aus dem  
Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie; CC 15  
Klinik für Neurologie  
Direktor: Prof. Dr. M. Endres

## **Habilitationsschrift**

# **Functional Imaging in Hereditary Dystonia**

zur Erlangung der Lehrbefähigung  
für das Fach Neurologie  
vorgelegt dem Fakultätsrat der Medizinischen Fakultät  
Charité-Universitätsmedizin Berlin  
von  
Dr. med. Maren Carbon-Correll

Eingereicht: Oktober 2013

Dekanin: Prof. Dr. med. Annette Grüters-Kieslich

1. Gutachter/in: Prof. Dr. med. Jens Volkmann

2. Gutachter/in: Prof. Dr. med. Günther Deuschl

# CONTENTS

|   |            |
|---|------------|
| <b>SUMMARY</b>  | <b>3</b>   |
| <b>A. INTRODUCTION</b>  | <b>4</b>   |
| <b>A.1. Classification of the Dystonias</b>   | <b>4</b>   |
| A.1.a. Clinical Classification  | 4          |
| A.1.b. Genetic Classification   | 5          |
| <b>A.2. Pathophysiology of Dystonia</b>   | <b>6</b>   |
| A.2.a. Human Morphological Studies  | 6          |
| A.2.b. Animal Models of Dystonia  | 7          |
| A.2.c. Neurophysiological Studies of Dystonia in Humans   | 9          |
| A.2.d. Imaging Studies of Human Dystonia  | 10         |
| <b>A.3. Aims and Hypotheses</b>   | <b>14</b>  |
| <b>B. RESULTS</b>   | <b>16</b>  |
| <b>B.1. Regional Metabolism in Primary Torsion Dystonia: Effects of penetrance and Genotype.</b>                  | <b>16</b>  |
| <b>B.2. Metabolic Changes in DYT11 Myoclonus-Dystonia.</b>  | <b>25</b>  |
| <b>B.3. Microstructural White Matter Changes in Carriers of the DYT1 Mutation.</b>                                | <b>34</b>  |
| <b>B.4. Microstructural White Matter Changes in Primary Torsion Dystonia.</b>                                     | <b>39</b>  |
| <b>B.5. Cerebellothalamocortical Connectivity Regulates Penetrance in Dystonia.</b>                               | <b>46</b>  |
| <b>B.6. Abnormal Striatal and Thalamic Dopamine Neurotransmission: Genotype-Related Features of Dystonia.</b>     | <b>55</b>  |
| <b>B.7. Increased Sensorimotor Network Activity in DYT1 Dystonia: a Functional Imaging Study.</b>                 | <b>63</b>  |
| <b>B.8. Increased Cerebellar Activation during Sequence Learning in DYT1 Carriers: an Equipperformance Study.</b> | <b>76</b>  |
| <b>B.9. Impaired Sequence Learning in Dystonia Mutation Carriers: a Genotypic Effect.</b>                         | <b>88</b>  |
| <b>C. DISCUSSION</b>  | <b>102</b> |
| <b>C.1. Metabolic and Microstructural Changes</b>   | <b>102</b> |
| C.1.a. Cerebellar Abnormalities   | 103        |
| C.1.b. Neurodevelopmental Abnormalities   | 105        |
| C.1.c. Parietal Abnormalities   | 106        |
| <b>C.2. Neurochemical Changes in Dystonia</b>   | <b>107</b> |
| C.2.a. The Dopaminergic System  | 107        |
| C.2.b. Perspective into Changes in Striatal Acetylcholine   | 108        |
| <b>C.3 Abnormal Network Activation in Dystonia</b>  | <b>108</b> |

|                        |            |
|------------------------|------------|
| <b>LITERATURE</b>      | <b>110</b> |
| <b>ACKNOWLEDGMENTS</b> | <b>126</b> |

**Abbreviations:** **BA:** Brodmann Area; **DRD:** dopa-responsive dystonia; **DTI:** diffusion tensor imaging; **FDG-PET:** fluorodeoxyglucose-PET; **<sup>18</sup>F-DOPA:** fluorine-18-L-dihydroxyphenylalanine; **GABA:** gamma-aminobutyric acid; **GTP:** guanosine 5' triphosphate cyclohydrolase; **MAN-DYT1:** manifesting DYT1 mutation carriers, **MAN-DYT6:** manifesting DYT6 mutation carriers; **MRI:** magnetic resonance imaging; **NM-DYT1:** non-manifesting DYT1 mutation carriers, **NM-DYT6:** non-manifesting DYT6 mutation carriers; **PET:** positron-emission-tomography; **PFC:** prefrontal cortex; **PreMC:** premotor cortex; **ROI:** region of interest; **SMA:** supplementary motor area; **SMC:** sensorimotor cortex; **SPM:** statistical parametric mapping.

## SUMMARY

The development of causal treatments of dystonia is hampered by the lack of a clear etiological understanding of the disease. The classical model has conceptualized dystonia as a hyperkinetic basal ganglia disorder (Albin et al., 1989). However, neither post-mortem studies in primary dystonias nor animal models of dystonia have unequivocally confirmed this concept. Similarly, earlier imaging studies in primary dystonia have yielded highly conflicting results.

Thus, this series of neuroimaging studies set out to test the hypothesis of primary dystonia as a developmental sensorimotor neurocircuitry disorder affecting brain regions beyond the striatum. To focus on an etiologically most homogenous group, DYT1 dystonia was chosen as a potential prototype disorder of the primary dystonias. Additional studies were also conducted in the DYT6 and DYT13 genotype. These genotypes are not fully penetrant, offering the possibility to study effects of susceptibility and disease separately.

Using a multi-modal imaging approach, including positron-emission-tomography with the tracers  $H_2^{15}O$ ,  $^{18}F$ -FDG and  $^{11}C$ -raclopride as well as magnetic resonance based diffusion tensor imaging, this series of studies supported the overarching hypotheses, showing that metabolic, microstructural and functional changes reach well beyond an isolated affection of the indirect striatal pathway, as suggested for hyperkinetic disorders traditionally (Albin et al., 1989). Similarly, a predominant role of dopaminergic neurotransmission within the basal ganglia was dismissed as hypothesized.

We demonstrated that functional changes of the striatum, both at the metabolic and the neurochemical level reflect the susceptibility for primary torsion dystonia (Carbon et al., 2004a, Carbon et al., 2009, Carbon et al., 2011; Carbon et al. 2013). By contrast, penetrance and disease severity did not relate to striatal characteristics, but were rather associated with the expression of a cortical sensorimotor brain activation network (Carbon et al., 2010). Nevertheless, downstream effects of striatal susceptibility-related changes in non-manifesting mutation carriers were found to manifest as sequence-learning deficits with concomitant cortical and cerebellar reorganization (Carbon 2004b, Carbon et al. 2008b, Carbon et al. 2011). Importantly, microstructural abnormalities underlying the expression of cortical sensorimotor network changes were found in the cerebellar outflow pathways in dystonia mutation carriers (Carbon et al. 2008a; Argyelan/Carbon et al., 2009). Interestingly, we found a novel interaction of cerebello-thalamic and thalamo-cortical connectivity as a potential mechanism regulating penetrance in the DYT1 and DYT6 genotype (Argyelan/Carbon et al., 2009). Thus, our data suggest that the functional entity of sensorimotor circuitry rather than one node within this network regulates symptom expression in dystonia.

## **A. INTRODUCTION**

Dystonia is a neurological syndrome that has classically been defined by “sustained muscle contractions, frequently causing twisting and repetitive movements or abnormal postures” (Marsden et al., 1987). This definition has recently been expanded to “a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. Dystonic movements are typically patterned, twisting, and may be tremulous. Dystonia is often initiated or worsened by voluntary action and associated with overflow muscle activation.” (Albanese et al., 2013).

Dystonia varies highly in clinical severity, but even in focal variants the quality of life is markedly reduced (Müller et al., 2002). Due to the lack of clear etiological understanding of the various dystonias, to date, all treatment options of dystonia are merely symptomatic (Jankovic, 2009). Importantly, a clearer understanding of mechanisms of disease would be needed for the development of causal therapies for dystonias of various etiologies. Thus, the objective of the following series of studies was a contribution to our understanding of mechanisms of disease in dystonia. This background section aims to provide a summary of the existing the body of knowledge on pathophysiology of dystonia, and of the current contribution of imaging studies to these concepts.

### **A.1. Classification of the Dystonias**

#### ***A.1.a. Clinical Classification***

Clinically, dystonia occurs in a vast variety of contexts, thus classifications of the dystonias are a topic of continued discussion (de Carvalho and Ozelius, 2002; Bressman, 2004; Albanese et al., 2013). The current consensus classification scheme categorizes the different dystonias by clinical characteristics (with sub-classification per age at onset, body distribution, temporal patterns and presence or absence of additional neurological features) and by etiological characteristics (with sub-classification by presence or absence of nervous system degenerative or macroscopic structural pathology and acquired vs. inherited etiology; Albanese et al., 2013). Importantly, despite these classification attempts, dystonias show considerable phenotypic variability with a huge overlap among different syndromes and etiologies, and at the same time a lack of consistent clinical-etiological correlations, both for genetic and for acquired causes.

For research, grouping strategies guided by current knowledge on biological mechanisms may be superior to clinical classification systems. Thus, in order to recruit cohorts with presumably most homogenous mechanisms of disease, genetically defined subgroups of primary dystonia (DYT1, DYT6, DYT11) were studied in this line of research. Of note, these cohorts were clinically mixed with regard to the body distribution of dystonia, thus minimizing the confounding effect of specific abnormal movement patterns.

### **A.1.b. Genetic Classification**

There are currently more than 20 genetic loci that have been associated with monogenic dystonias (Petrucci and Valente 2013). These can be grouped into the three major clusters, of isolated dystonia (including the DYT1 and DYT6 genotype amongst others), dystonia plus syndromes (e.g. DRD, DYT11) and paroxysmal dystonias. Among these, the gene product is known for DYT1 (gene coding for torsinA), DYT6 (gene coding for THAP1), DRD (gene coding for GTP-Cyclohydroxylase/GTPCH1) and DYT11 (gene coding for epsilon sacroglycan); and most recently for DYT4 (gene coding for  $\beta$ - tubulin 4a; Hersheson et al., 2013).

However, the functions of the different gene products in health and disease are still a topic of current research, and a common pathway for these proteins does not seem to evolve. To date, genetic studies do not converge on the involvement of a specific neurotransmitter system or another common pathway to be involved in the dystonias, nor have they implied a common brain region predominantly involved in the dystonias. Rather the presence of numerous genotypes without clear genotype-phenotype association invites the speculation that multiple brain regions and/or neurotransmitter systems can be involved in the various forms of dystonias. In this context, the subsequent series of studies was designed to deepen our understanding of hereditary dystonias, assuming that these monogenic diseases might serve as prototype disorders and that mechanisms of disease identified in one disorder would provide testable hypotheses for the more frequent, but yet even more heterogeneous sporadic dystonias. Thus, the most frequent hereditary dystonia, DYT1 dystonia, was studied as a prototype disorder to help identify mechanisms of disease that could be translated to sporadic dystonias in the future.

DYT1 dystonia is clinically characterized by an early onset, often starting in one limb (leg) and spreading during the prepubertal period throughout the body. In addition to this typical course of ultimately generalized dystonia, DYT1 dystonia can also manifest as isolated task-related or simple focal dystonia. DYT1 dystonia is inherited as an autosomal dominant DYT1 mutation on gene 9q34 representing a GAG deletion within the coding area for torsinA (Ozelius et al., 1997). This deletion, however, causes clinical manifestations of dystonia in only 30% of mutation carriers (Bressman et al., 1994).

DYT6 dystonia represents another less frequent autosomal dominant variant of primary torsion dystonia, which has been characterized in North America Mennonites (Almasy et al., 1997). DYT6 had been linked to a mutation on chromosome 8 (8p11-8q13), but had not yet been fully identified at the beginning of our studies. In 2009, the DYT6 mutation was identified as a missense mutation of the THAP1 gene (Fuchs et al., 2009). Clear factors determining penetrance have not been identified in both genotypes.

DYT 11 represents the most frequent genetic variant of myoclonus dystonia and has been related to various loss of function mutations in the epsilon-sarcoglycan gene (SGCE) located on chromosome 7q21 (Zimprich et al., 2001, Valente et al., 2005).

## **A.2. Pathophysiology of Dystonia**

Dystonia has traditionally been conceptualized as hyperkinetic basal ganglia disorder (Vitek et al., 1999). This pathophysiological concept has been derived from lesion studies of secondary dystonias, involving the basal ganglia (Bhatia and Marsden 1994) and from several lines of evidence that strongly suggested a key function of the dopaminergic system in dystonia (Hornykiewicz et al., 1986; Ichinose et al., 1999; Wichmann, 2008). However, a seminal cohort study on secondary dystonia disclosed an important contribution of the cerebellum and its afferents (Ledoux and Brady 2003). Currently, mounting evidence confirms a prominent role of these regions in conjunction with sensorimotor circuitries (Eidelberg et al., 1998; Tanabe et al., 2009; Neychev et al., 2009).

In the following section, the contributions of different research techniques to our understanding on pathophysiology of dystonia will be summarized. Notably, this body of knowledge has continuously broadened from the traditional view of dystonia as a basal ganglia disorder throughout the period of conduction and publication of the studies summarized subsequently. Thus, parallel gains of knowledge from fields, other than imaging, will be summarized in the introduction, even though some of them had not yet been detected at the time of our studies. The introductory section regarding imaging was restricted to knowledge up to 2004 as this reflects the starting point of this line of work; the subsequent evolution is discussed in the context of the studies and the summarizing discussion.

### **A.2.a. Human Morphological Studies**

The earliest postmortem study on idiopathic childhood onset generalized dystonia (n=2), reported a lack of histopathological abnormalities, normal levels of acetylcholine, GABA and glutamate, but reduced dopamine levels in the striatum in one subject and reduced levels of norepinephrine in the subthalamic nucleus, the hypothalamus, the mammillary bodies and locus ceruleus in both subjects (Hornykiewicz et al., 1986). However, subsequent postmortem studies in sporadic primary dystonias have failed to provide consistent findings (for review see Standaert, 2011). Similarly, postmortem studies in DYT1 dystonia have yielded inconsistent results with normal regional distribution of torsinA in the adult brains (Walker et al., 2002; Rostasy et al., 2003), but modest changes in dopamine metabolites suggestive of altered dopamine turnover (Furukawa et al., 2000; Augood et al., 2002). The most detailed study in four DYT1 dystonia autopsy cases revealed ubiquitin-torsinA-positive inclusions in brainstem regions, including neurons of the pedunculopontine tegmental

nucleus, the cuneiform nucleus, and periaqueductal gray matter, but not in striatal or cortical regions (McNaught et al., 2004). Importantly also no association with the dopaminergic system was found, instead the inclusions co-localized with cholinergic markers (McNaught et al., 2004).

### ***A.2.b. Animal Models of Dystonia***

Similarly, results from animal models of dystonia have not led to a conclusive understanding of the disorder yet, because to date there is no model that combines a clear etiology with a clear dystonic phenomenology (LeDoux, 2011; Jinnah et al., 2009). Phenomenological and etiological rodent models, as well as - to a lesser degree - primate models contribute different aspects to considerations on potential mechanisms of disease in humans.

#### *A.2.b.i. Phenomenological Models*

Phenomenological models show abnormal movement patterns reminiscent of human dystonia, which were serendipitously detected as natural variants in breeding colonies. These include the spontaneously dystonic *dt* rat (Lorden et al., 1984), the tottering mouse (Green and Sidman, 1962), and the dystonic (*sz/dt*) hamster (Nobrega et al., 1995). While the *dt* rat is considered closest to primary dystonia, both the *sz/dt* hamster and the tottering mouse reflect paroxysmal dystonia. Moreover, the attacks of the tottering mouse are highly stereotyped beginning in the lower extremities and further expanding to the upper extremities and the trunk. Unlike humans with primary dystonia, however, tottering mice and the *sz/dt* hamster have normal motor abilities between the attacks.

Even though the *dt* rat is clinically severely affected with postnatal progressive axial and appendicular dystonia leading consistently to death, no obvious abnormalities of brain morphology were found (Lorden et al., 1984, LeDoux et al., 1995) and extensive studies of basal ganglia morphology and neurochemistry similarly failed to identify abnormalities (Mc Keon et al., 1984). A subsequent series of studies regarding cerebellar morphology in the *dt* rat revealed normal Purkinje cell number and arborization, normal volume of the cerebellar nuclei, normal soma size of cerebellar nuclear neurons, normal molecular and granular cell layer thickness and normal cerebello-olivary connectivity patterns. Only the size of Purkinje cells of the vermis and paravermis at postnatal day 20 was slightly reduced (5–11%; Lorden et al., 1992). Despite the paucity of morphological abnormalities, markers of functional activity of the cerebellar cortex were found to be abnormal: Spontaneous Purkinje cell firing rates were reduced (Stratton et al., 1988), cyclic guanosine monophosphate (cGMP) was found to be decreased in rat cerebellar cortex (Lorden et al., 1985), and the activation response to chemically induced activation or electrical activation was found to be attenuated (Stratton et al., 1988; Lorden et al., 1985). These changes were suggested to relate to



increased activity of GABAergic projections of Purkinje cells onto deep cerebellar nuclei (LeDoux, 2011). Indeed, the crucial role of the cerebellum in the *dt* rat was proven in experiments where cerebellectomy prior to the expression of the dystonic syndrome prevented the development hereof and led to survival past adulthood (LeDoux et al., 1993). Notably though, with regard to etiological aspects this animal model clearly differs from human causes of primary dystonia: the mutation responsible for this *dt* rat was localized to the ATCAY gene (Xiao and Ledoux, 2005), but mutations within the human ATCAY gene lead to a syndrome of combined mental retardation, gait ataxia, intention tremor, nystagmus and dysarthria, but not to dystonia (Bomar et al., 2003).

#### *A.2.b.ii. Etiological Models - Genetic*

Among etiological animal models genetically engineered mouse models are most relevant to the subsequently summarized line of work in humans. Unfortunately however, all transgenic mouse models with heterozygous expression of the human DYT1 mutation failed to replicate motor abnormalities clearly reminiscent of human dystonia or interfering with breeding and survival (cf. Jinnah et al. 2008). Considering the 30% penetrance for the DYT1 mutation in humans (Bressman et al. 1994), it would not be surprising to find only certain subgroups of transgenic animals to be affected, however a clear clustering of motor abnormalities has not been reported in any of the transgenic models. Nevertheless, even in the absence of overt dystonia, certain pathophysiological aspects thought to be important in human dystonia were found in some transgenic models, albeit with very moderate impact: Increased striatal DA turnover appears to be the most consistent finding, demonstrated in three models, in which the observed motor abnormalities consisted of self-clasping behavior during the tail suspension test (Shashidharan et al., 2005), decreased dexterity during beam walking (Zhao, 2008) and impaired motor learning skills (Balcioglu et al., 2007). In addition, a mutant DYT1 knock-in mouse model showed minimal motor abnormalities upon extensive testing and slight reductions in striatal dopamine in male mice, but not in females (Dang et al., 2005) and a torsinA knock-down mouse model reported slightly abnormal open field activity and dexterity in beam walking in male mice, but not in females along with slightly reduced metabolites of dopamine (Dang et al., 2006).

#### *A.2.b.iii. Etiological Models – Induced Lesions*

Analogous to lesion locations identified in secondary dystonias, animal models using direct surgical or chemical lesion techniques were introduced. Indeed, using these techniques (in contrast to genetic modeling), overt dystonia could be convincingly reproduced in mammals. However, in these models the relationship to idiopathic dystonia, which is the most frequent type in humans and which lacks clear lesional findings, may be rather limited. The value of

these models, however, lies in providing testable hypotheses for mechanisms of disease in idiopathic dystonia and in providing models for pharmacological testing.

Generalized and segmental dystonia has been modeled in rodents with chemical lesions of the basal ganglia (Guyot et al., 1997), the cerebellum (Pizoli et al., 2002) and the brainstem red nucleus (Walker et al., 1988). Interestingly, a line of early research has demonstrated the induction of (mostly transient) cervical dystonia with lesions of the ventral tegmental area, including the interstitial nucleus of Cajal (Foltz et al., 1959, Battista et al., 1976, Sambrook et al., 1979, Mori et al., 1985). Though the ventral tegmental area mainly contains dopaminergic neurons, there are serotonergic neurons close to its border, and the torticollis inducing lesions were neurochemically associated with a reduction of serotonin in the caudate nucleus (Miyake, 1988).

Models of maladaptive sensorimotor integration have been used for other focal dystonias. Of particular interest was the blepharospasm model developed by Schicatano and colleagues (1997), as this two-hit model may be close to the situation in humans, where the specific combination of subthreshold internal and external factors results in the manifestation of symptoms. In this model, an incomplete brainstem dopamine depletion (as can be present in aging) and an incomplete denervation of the orbicularis oculi muscle (representative of an unspecific ocular irritation) led to the manifestation of blepharospasm in the rat.

Another important model of focal dystonia closely parallels task induced dystonias, as it represents consequences of strenuous overuse (Byl et al. 1996), emphasizing the environmental aspect over the internal one. In this model affected primates, who had been trained to perform highly stereotyped, repetitive hand movements, show dedifferentiated somatosensory cortices, relating to the observation of increased cortical neuronal plasticity, discussed for humans below.

### ***A.2.c. Neurophysiological Studies of Dystonia in Humans***

Electrophysiological studies have consistently shown impaired inhibition, increased neuronal plasticity, and/or abnormal sensory processing in dystonias of various clinical subtypes and origins (Hallett, 2011). Inhibitory loss has been demonstrated at key levels of the central nervous system, i.e. the spinal, brainstem and cortical level (Hallett, 2011). Loss of inhibitory cortical function can be considered the neurophysiological hallmark of dystonia, but exactly how this common downstream pathway is generated remains a topic of current research, where dysfunction of the basal ganglia, the brainstem and the cerebellum alone or combined or interrelated are being discussed. Classically, cortical dysinhibition has been explained as a failure of cortico-striato-pallidal-thalamo-cortical circuit (CSPTC) function; i.e. involuntary movements were interpreted as a failure to select the appropriate movement pattern and to inhibit non-selected “overflow” movement”. In this regard, frequency reductions in pallidal

output have been recorded in vivo in humans with dystonia (Silberstein et al., 2003; Starr et al., 2005; Nambu et al., 2011; Nishibayashi et al., 2011), and in DYT1 transgenic mice (Chiken et al., 2008). The finding of impaired cortical inhibition was corroborated in transcranial magnetic stimulation (TMS) studies (Quartarone et al., 2006; Rothwell, 2007; Di Lazzaro et al., 2009), which showed both, the loss of short and long intracortical inhibition as well as a decreased silent period. While these studies clearly capture the pathophysiology of the dystonic movement as such, the etiological role of these cortical changes could not be identified, particularly, considering that neither lesion studies, nor postmortem histopathology, nor animal models have isolated the potential pathology to cortical structures.

Abnormally reduced pallidal firing frequencies have directly been measured in patients undergoing surgery for deep brain stimulation for primary dystonia (Silberstein et al., 2003; Starr et al., 2005; Weinberger et al., 2012). Similarly, dystonia related to dopamine depletion was linked to low pallidal frequencies (Kühn et al., 2008). By contrast, in a single patient with a striatal stroke, however increased rates of bursting pallidal neurons were found (Fuller et al. 2013). Subthalamic nucleus rates have been found to range higher than normal in primary adult onset dystonia (Schrock et al. 2009). Close correlations of subthalamic neuronal activity (Zhuang et al., 2004; Neumann et al. 2012) or pallidal neuronal activity (Chen et al. 2006) and dystonia-related EMG activity were observed in primary and secondary dystonia.

Closely related to the loss of inhibition at several levels is the observation of increased neuronal plasticity in dystonia (Classen, 2003; Siebner et al., 2003; Quartarone et al., 2006). Along these lines, magnetencephalography showed altered cortical representation patterns, with reduced distances of motor and sensory representations of single digits of dystonic hands (Elbert et al., 1998; Braun et al., 2003).

In summary the plethora of neurophysiological studies of various forms of dystonia clusters around the observation of impaired neuronal inhibitory control at various levels and with widespread consequences. The identification of the origins of these abnormalities has however been beyond the scope of neurophysiology.

#### ***A.2.d. Imaging Studies of Human Dystonia***

Compared to neurophysiological techniques, which typically target one functional system at a time, neuroimaging techniques offer a non-invasive in vivo whole-brain overview of specific tissue characteristics or of functional reactivity (depending on the method used). On one hand this broadens the scope of the measurements on the other hand causal inferences of observations are clearly limited.

Despite the promising nature of neuroimaging, imaging studies of dystonia have yielded highly conflicting results, which is in stark contrast to the rather consistent findings of neurophysiological studies. Differences in specific techniques, study design and analytical techniques likely contribute to the inconsistencies. It is possible though, that the heterogeneity also reflects the true variety in mechanisms of disease (identified in imaging), which in turn lead to a common downstream pathway (identified in neurophysiology).

As mentioned above, this introductory chapter will be restricted to the background of neuroimaging studies prior to the start of the subsequently summarized series of studies in hereditary dystonia.

#### *A.2.d.i. MRI Based Studies of Dystonia*

*Voxel-based morphometry (VBM):* VBM as a basic structural technique provides data of regional brain volumes using T1-weighted MRI scans. Using this technique, volumetric increases of basal ganglia structures were shown in patients with blepharospasm or focal hand dystonia (Black et al., 1998), in cervical dystonia (Draganski et al., 2003) and in DYT1 dystonia (Draganski et al., 2009). Volumetric increases were noted in cervical dystonia in the SMA, in the PFC, and in the visual cortex (Draganski et al., 2003) and in the primary sensory cortex and in the primary motor cortex in focal hand dystonia (Garraux et al., 2004).

*Functional MRI (f-MRI):* Up to 2004, there were only a few functional MRI studies due to the limited availability at that time and all of them only included subjects with various focal dystonia (as opposed to the clinically mixed series of hereditary dystonia summarized here). Studies using motor paradigms devoid of inducing overt dystonia during imaging in focal hand dystonia found decreased SMC and SMA activation during contraction and relaxation without concomitant activation increases (Oga et al., 2002) and increased, persistent basal ganglia, primary motor cortex and sensory motor cortex activation without concomitant activation decreases (Blood et al., 2004). In addition, other f-MRI studies in focal hand dystonias using motor paradigms with dystonic movement during the scanning found increased primary motor cortex activation (Preibisch et al., 2001; Pujol et al., 2000) and increased cerebellar activation (Preibisch 2001), as well as decreased premotor cortex activation (Pujol et al., 2000). In blepharospasm, abnormal putaminal activation was recorded selectively during periods of the spasm (Schmidt et al., 2003).

f-MRI studies using sensory paradigms showed altered processing of simultaneous inputs (Sanger et al., 2002; Butterworth et al., 2003, Delmaire et al. 2005) and increased basal ganglia activation (Peller et al. 2006) In parallel to the findings of the primate overuse model of dystonia, altered somatotopy was found with reduced distances of cortical representations of single digits during vibro-tactile stimulation (Butterworth et al., 2003).

The heterogeneity of functional activation studies, despite comparable disease cohorts, may result from differences in (1) activation paradigms, (2) baseline states, and (3) analytical techniques as well as from the fact that these studies typically involve rather low numbers of subjects due to the difficulty to recruit affected subjects and due to the necessity to perform these studies during a tight time frame to avoid drift in scanner measures.

*MR based spectroscopy:* Consistent with the observation of reduced inhibition at many levels of the central nervous system, one small study using MR based spectroscopy of GABA metabolites in writer's cramp (n=7) reported significant reductions in the GABA levels of the SMC and lentiform nuclei contralateral to the affected hand (Levy and Hallett 2002). A later, larger, confirmatory study (n=22) by the same workgroup in a similar cohort (task specific hand dystonia), however, failed to reproduce this observation (Herath et al., 2010).

#### *A.2.d.ii. Positron-Emission-Tomography Studies of Dystonia*

*Activation Studies:* Motor activation studies using radiolabeled water or oxygen and PET were conducted, contrary to the fMRI studies, in cohorts of focal dystonia and in segmental or generalized dystonia. A series of studies by Ceballos-Baumann and colleagues showed increased activation of the premotor cortex (PreMC) and SMA in acquired hemidystonia (Ceballos-Baumann et al., 1995a) and in idiopathic torsion dystonia (Ceballos-Baumann et al., 1995b). However, putaminal overactivation was only found in idiopathic torsion dystonia (Ceballos-Baumann et al., 1995b), whereas cerebellar overactivation was only found in acquired hemidystonia (Ceballos-Baumann et al., 1995a). Moreover, contrary to the f-MRI studies, *decreases* in primary motor cortex studies were reported in his studies (Ceballos-Baumann et al., 1995a,b; 1997), as well as in another seminal study of idiopathic torsion dystonia (Playford et al., 1998). In the latter study, similar to the first studies by Ceballos-Baumann, increases in PreMC, SMA, cerebellum and putamen were reported. By contrast, the three studies (up to 2004) in writer's cramp showed opposing results, reporting *decreased* PreMC and primary motor cortex activation (Odergreen et al., 1998) but also *increased* PreMC (Lerner et al.; 2004; Ibanez et al., 1999) and primary motor cortex activation (Ibanez et al.; 1999). Yet different results were reported for dorsolateral-prefrontal cortex (DLPFC) activation during motor tasks, where abnormal overactivation was seen in patients with primary generalized dystonia with deep brain stimulation during the OFF period with a normalization during the ON period (Detante et al., 2004). Similarly, another PET study in a single patient with GPi DBS (Kumar et al., 1999) characterized the effect of stimulation as reduced activation in the primary motor cortex, PreMC, SMA and DLPFC.

The heterogeneity of results was however less apparent in the few studies focusing on sensory paradigms, which confirmed the observation of abnormal sensorimotor integration in dystonia (Tempel and Perlmutter 1990; Feiwell et al., 1999).

*Resting state studies:* Considering that motor activation paradigms may be subject to a variety of confounds in dystonia, PET studies into glucose metabolism in dystonia were expected to yield more consistent results. PET studies using radiolabeled glucose in focal dystonia had been conducted in blepharospasm mainly (Esmaeli-Gutstein et al., 1999; Hutchinson et al., 2000; Kerrison et al. 2003), but also in cervical dystonia (Magyar-Lehmann et al. 1997). Three of these found increased metabolism in basal ganglia circuits, however all in varying topographies, i.e. in the striatum (Magyar-Lehmann et al., 1997; Esmaeli-Gutstein et al. 1999) in the caudate (Kerrison et al., 2003) and in the thalamus (Esmaeli-Gutstein et al., 1999). It has to be noted though, that some of these earlier studies accepted significance thresholds that would no longer be considered significant by current standards. Contrasting to the other studies, only one found pontine and cerebellar hypermetabolism (Hutchinson et al., 2000).

In a series of PET studies using FDG and spatial covariance analysis (Alexander and Moeller 1994) an abnormal idiopathic torsion dystonia related network was identified (Eidelberg et al., 1995). This network showed relative hypermetabolism of prefrontal and paracentral regions in conjunction with striatum, pons and midbrain. Interestingly, the intensity of this network correlated with the clinical severity of dystonia. After the identification of the DYT1 genotype (Ozelius et al. 1997) a DYT1-specific metabolic brain network was derived from scans in NM-DYT1. This network was characterized by relative increases in the posterior putamen, cerebellum and SMA (Eidelberg et al., 1998). Importantly, abnormal DYT1-specific metabolic network activity was demonstrated in symptomatic DYT1 carriers when involuntary dystonic movements were suppressed by sleep induction (Eidelberg et al., 1998). This ROI-based network was subsequently confirmed using voxel-based analyses (Troost et al., 2002). The extension of this work into the DYT6 genotype is one of starting points of work presented later (cf. Chapter B.1).

*Neurotransmitter studies:* A unique quality of PET is the ability to analyze neurotransmitter profiles. Ample evidence suggests a role of dopaminergic neurotransmission in symptoms of dystonia; particularly the clinical observations of DRD, antipsychotic induced acute or tardive dystonia (e.g., Burke et al., 1982; Factor and Matthews, 1991; Casey, 2004). Moreover, a number of secondary dystonias appear to be solely caused by abnormalities of dopaminergic transmission, as has been documented by PET studies (Ernst et al., 1996; Wong et al., 1996; Brashear et al., 1999, Asanuma et al., 2005).

PET studies have reported abnormalities of dopaminergic neurotransmission with reduced striatal D<sub>2</sub> receptor availability in cervical dystonia (Hierholzer et al.; 1994, Naumann et al.; 1998), in focal hand or cranial dystonia (Perlmutter et al., 1997). Notably, in the most severely affected cases, in generalized idiopathic torsion dystonia, <sup>18</sup>F-DOPA uptake, as a correlate of dopamine decarboxylase activity was only slightly reduced in the majority of

dystonic patients studied, with only three of eleven subjects showing values clearly outside the normal range (Playford et al., 1993).

### **A.3. Aims and Hypotheses**

The overview on the body of knowledge on pathophysiology in dystonia (particularly at the time of the start of these projects) illustrates that a deep understanding of the disease is clearly lacking, even though this is sorely needed to develop treatment strategies beyond mere symptomatic treatment. In particular, the data from human post-mortem, neurophysiological and imaging studies in conjunction with those from animal models question the simplistic model of dystonia as a hyperkinetic basal ganglia disorder. Abnormalities on the cortical level, the basal ganglia level, the brainstem level and the cerebellar level were convincingly and repeatedly shown in different studies, and thus needed to be integrated. A contribution to the development of an integral model was the ultimate aim of this series of studies.

It was and is uncertain though whether or not the dystonias are unified by a common mechanism of disease, or whether multiple mechanisms can lead to a similar clinical manifestation or to a shared downstream pathway. To study cohorts with a high likelihood of a unifying mechanism of disease, we chose to study hereditary dystonias. In particular DYT1 dystonia was a focus, as this mutation was identified as of 1997 as an autosomal dominant DYT1 mutation on gene 9q34 representing a GAG deletion within the coding area for torsinA (Ozelius et al., 1997). The studies were then expanded into carriers of the DYT6 genotype, even though at the time the studies the gene had not yet been identified.

#### **The overarching hypotheses tested in the subsequent studies were:**

1. Based on earlier imaging studies (Eidelberg et al., 1995; Trost et al., 2002), we hypothesized that *hereditary dystonia is associated with a network of functional changes in primary and secondary motor cortices, in conjunction with changes in basal ganglia and cerebellar structures* rather than with isolated dysfunction of the indirect striatal pathway as posited earlier (Albin and Young, 1989). This hypothesis was tested:
  - a. in manifesting and non-manifesting DYT1, DYT6 and DYT 11 mutation carriers using voxel-wise analyses of brain glucose metabolism as measured in FDG PET (**B.1.:** Carbon et al., 2004a; **B.2.:** Carbon et al., 2013),
  - b. in manifesting and non-manifesting DYT1 and DYT6 mutation carriers using voxel-wise analyses of microstructural connectivity data as measured with DTI-MRI scans (**B.3.:** Carbon et al., 2004b; **B.4.:** Carbon et al., 2008a; **B.5.:** Argyelan/Carbon et al., 2009) and

- c. in manifesting and non-manifesting DYT1 and DYT6 mutation carriers using voxel-wise analyses of D<sub>2</sub> receptor binding as measured in raclopride PET (**B.6.:** Carbon, 2009a).
- 2. Based on our findings in the resting state, we hypothesized that a complex interaction of network changes mediates cortical activation changes in genetically prone individuals. This hypothesis was tested:
  - a. in manifesting and non-manifesting DYT1 mutation carriers using voxel-wise analyses of brain activation H<sub>2</sub><sup>15</sup>O-PET studies during simple paced motor tasks (**B.7.:** Carbon et al., 2010a). [Extending data of a small cohort of subjects with sporadic dystonia and with deep brain stimulation will also be included.]
  - b. in manifesting and non-manifesting DYT1 mutation carriers using voxel-wise analyses of brain activation H<sub>2</sub><sup>15</sup>O-PET studies during motor sequence learning (**B.10.:** Carbon et al. Brain 2008b; **B.11.:** Carbon et al. 2011).

To date, the entire series of studies involved 25 manifesting (MAN) and 18 non-manifesting (NM) DYT1 mutation carriers, and 11 MAN-DYT6 and 13 NM-DYT6 mutation carriers. The majority of these subjects were scanned in the resting state with <sup>18</sup>F-FDG PET. Different subgroups were additionally imaged with: (1) <sup>15</sup>O-water (H<sub>2</sub><sup>15</sup>O) PET to assess the effects of genotype and phenotype on regional activation responses during motor performance and sequence learning; (2) MRI-DTI to assess corresponding changes in anatomical connectivity as well as (3) <sup>11</sup>C-raclopride to examine the role of striatal D<sub>2</sub>-receptor binding in mediating these functional/anatomical changes. A separate cohort with myoclonus dystonia (DYT11) was scanned with <sup>18</sup>F-FDG PET. Moreover, ongoing studies have included subjects with sporadic dystonia as well as subjects with deep brain stimulation in ON/OFF states. Additional pilot studies have transferred the PET studies to f-MRI technique.

The prime methodological advantage of our studies is the inclusion of clinically unaffected, non-manifesting mutation carriers. In this regard, we have taken care not to recruit preclinical subjects as non-manifesting subjects. This is possible due to the typically early age of manifestation, around the age of 8 years in DYT1 dystonia, and around puberty in DYT6 dystonia. Considering the spread of manifestation ages up into adulthood, non-manifesting subjects were required to be 30 years at minimum.



## B. RESULTS

### B.1. Regional Metabolism in Primary Torsion Dystonia: Effects of penetrance and Genotype. (Carbon et al. 2004a)

To reduce the heterogeneity of findings of various dystonia cohorts, genotype specific abnormalities were sought in specified subgroups. Eidelberg and colleagues (1995) identified a network of symptom-specific metabolic increases in the lateral frontal and paracentral cortices, and the striatum, pons and midbrain in idiopathic, predominantly right-sided dystonia. It was however unclear, whether or how many DYT1 positive subjects had been included in that study, as this genotype had not been identified at the time of the study. After the identification of the DYT1 genotype as one genetic variant of idiopathic generalized dystonia (Ozelius et al., 1997), a first DYT1-specific metabolic brain network was described using volume-of-interest measurements in conjunction with principal components analysis (Eidelberg et al. 1998). This network was characterized by relative metabolic increases in the posterior putamen, globus pallidus, cerebellum and SMA in patients with focal or generalized DYT1 dystonia (Eidelberg et al., 1998) and subsequently validated on a voxel-based level (Trost et al., 2002).

In the amended study, DYT1-specific metabolic changes were compared to the metabolic topography in the DYT6 genotype. Based on preliminary studies in this genotype (Trost et al. 2002), and based on the clinical similarities of both genotypes, we hypothesized that metabolic abnormalities would largely overlap. <sup>18</sup>F-FDG PET was used to scan 12 MAN-DYT1 and 11 NM-DYT1, six NM-DYT6 and seven MAN-DYT6, as well as 11 control subjects. The data from all five groups were analyzed with SPM99 and analysis of variance (ANOVA) with posthoc contrasts.


Contrasting to our hypothesis, we found a dissociation of metabolic changes related to phenotype and genotype. Manifesting gene carriers of both genotypes exhibited bilateral hypermetabolism in the presupplementary motor area (BA 6) and parietal association cortices (BA 40/7) compared with the respective non-manifesting counterparts. By contrast, genotype-specific increases in DYT1 mutation carriers (manifesting and non-manifesting combined, with no within-group differences) were localized to the putamen, anterior cingulate (BA 24/32), and to both cerebellar hemispheres. The DYT6 genotype showed opposing metabolic changes, involving hypometabolism of the putamen and hypermetabolism in the temporal cortex (BA 21).

As a conclusion, we suggested that the susceptibility to dystonia related to an imbalance of cerebellar and basal ganglia metabolism. Moreover, symptoms of dystonia may be

associated with abnormal movement preparation reflected by metabolic increases in the motor preparatory cortices and relating to defective sensorimotor integration reflected by metabolic increases in parietal association cortices.

Well after this publication, sequence variants within the coding region of the DYT1 gene were identified (Kock et al., 2006). One of these variants, a single nucleotide polymorphism, occurring in 12% of subjects, consisted in a substitution of aspartic acid (D) for histidine (H216, Kock et al., 2006). The H216 polymorphism was found to reduce cell inclusions that are typically seen in cells expressing the DYT1 mutation ( $\Delta$ GAG). Interestingly, Risch and colleagues (2007) found an unexpected proportion of NM-DYT1 to carry this additional polymorphism. Thus, the H216 polymorphism was suggested to be protective with regard to

dystonia pathology. In a pilot study, we tested the effect of this protective polymorphism in our cohort of NM-DYT1 (Carbon et al., 2008c). Resting state FDG PET scans were performed in 13 MAN-DYT1 (age  $39.9 \pm 15.1$  years), three 216H/NM-DYT1, five D216/NM-DYT1; NM-DYT1 age  $55.9 \pm 14.7$  years), and 12 healthy controls matched to NM-DYT1



(age  $52.7 \pm 13.8$  years). Volume of interest (VOI) based measurements of the phenotype specific regions, identified earlier (Carbon et al., 2004a) were performed. We found metabolic values of pre-SMA and inferior parietal cortex (i.e. phenotype specific regions) in unprotected mutation carriers (216D-NM-DYT1) to fall within the range of MAN-DYT1. By contrast, those carrying the protective polymorphism (H216-NM-DYT1) showed metabolic values within the control range in the respective regions (see Figure 1; Carbon et al. 2008c).

**p. 18 - 24:**

Carbon M, Su S, Dhawan V, Raymond D, Bressman S, Eidelberg D. Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. *Neurology*. 2004 Apr 27;62(8):1384-90. PubMed PMID: 15111678. DOI 10.1212/01.WNL.0000120541.97467.FE

## **B.2. Metabolic Changes in DYT11 Myoclonus-Dystonia.** (Carbon et al., 2013)

Expanding on the findings in the DYT1 and the DYT6 genotype, we aimed to identify brain regions with metabolic abnormalities in a dystonia plus syndrome, i.e. in DYT11 myoclonus-dystonia (DYT11-MD). We also compared these metabolic abnormalities in DYT11-MD with those found in other forms of hereditary dystonia and in posthypoxic myoclonus.

As in our earlier study, <sup>18</sup>F-FDG PET of the brain during the resting state was performed in six subjects with DYT11-MD (age 30.5 ± 10.1 years) and in 6 NM DYT11 (age 59.1 ± 8.9 years) representing the parental generation of the affected individuals. We used voxel-based whole brain searches implemented in SPM5 to compare these data to scan data from age-matched healthy control subjects. As a secondary analysis, we searched for shared characteristics of either one of the hereditary dystonias and the DYT11 dystonia-plus syndrome; or shared characteristics of posthypoxic dystonia and the DYT11 dystonia-plus syndrome. These overlapping abnormalities were identified by comparisons of the DYT11-MD subjects to hereditary dystonias (DYT1, DYT6, DRD) and to posthypoxic myoclonus.

Surprisingly, we found DYT11 genotype-specific metabolic abnormalities. This finding was completely unexpected as NM-DYT11 are expected not to show any changes in epsilon-sarcoglycan, since gene expression is thought to be strictly regulated via maternal imprint. The genotype-specific metabolic abnormalities, however, were present independently in comparisons of the paternal as well as the filial (manifesting) generation with age-matched healthy subjects respectively. The significant DYT11 genotype-specific changes included metabolic increases in the inferior pons and in the posterior thalamus as well as reductions in the ventromedial PFC. As with the DYT1 and the DYT6 genotype, additional significant phenotype-related increases were present. These were localized to the parasagittal cerebellum. Interestingly, this latter abnormality was shared only with posthypoxic myoclonus, but not with other forms of hereditary dystonia. By contrast, all dystonia cohorts exhibited significant metabolic increases in the superior parietal lobule in concordance with the metabolic abnormalities localized to this region in the earlier study of DYT1 and DYT6 dystonia.

The manifestation related findings were highly consistent with earlier imaging reports on single cases with DYT11 dystonia (Nitschke et al., 2006; Tai et al., 2009). They were consistent with a subcortical myoclonus generator in DYT11-MD, likely involving the cerebellum. Such a generator had been suggested in a preceding neurophysiological study (Hubsch et al., 2011).

Contrasting to the genotype specific findings, rather subtle increases in the superior parietal cortex related to the additional presence of dystonic symptoms, again most likely pointing to a deficit of sensorimotor integration in dystonia.

Despite clear evidence for the regulation of penetrance in DYT11-MD with maternal imprinting of the epsilon-sarcoglycan gene (Müller et al., 2002), NM-DYT11 (who should thus not express the mutated protein) showed significant metabolic abnormalities that were not explained by this genetic model. Indeed, these findings were very difficult to reconcile with this notion of maternal imprinting of the SGCE gene. It has to be noted though, that abnormal motor activation responses obtained during f-MRI had been reported in NM-DYT11 earlier (Beukers et al., 2010, 2011), similarly questioning the dogma of maternal imprint as the sole regulator of penetrance during adulthood. In our discussion on this topic we suggested, that maternal imprinting is not a binary, all-or-nothing regulator of gene penetrance. To support this idea, evidence for variations of maternal imprinting by species, tissue, and developmental stage is detailed in the manuscript. Consistent with the idea of hereditary dystonias as neurodevelopmental disorders (disease onset of DYT11 dystonia is typically during childhood or adolescence), imprinted genes have been shown to play an important role during embryogenesis and neurodevelopment. This means that the expression of imprinted genes can change during development, tissue differentiation and during disease (Taniguchi et al., 1995; Davies et al., 2005; Schulz et al., 2006; Hudson et al., 2010). In particular, a loss of imprinted expression during cellular differentiation can be present in a tissue-specific manner. For epsilon-sarcoglycan, a weak (non-expected) maternal expression, in addition to the (expected) paternal expression, has been shown in adult rodent neuronal cells (Piras et al., 2000), even though the maternal imprint was maintained in neonatal and embryonic brain tissue. We have thus suggested from our data, that it is possible that a biallelic expression of epsilon-sarcoglycan is needed during certain periods of neurodevelopment, during which a loss-of-function mutation in the maternal allele (as is posited for DYT11-MD) causes the metabolic abnormalities recorded in our study.

**p. 27 - 33.**

Carbon M, Raymond D, Ozelius L, Saunders-Pullman R, Frucht S, Dhawan V, Bressman S, idelberg D. Metabolic changes in DYT11 myoclonus-dystonia. *Neurology*. 2013 Jan 22;80(4):385-91. doi: 10.1212/WNL.0b013e31827f0798. Epub 2013 Jan 2. PubMed PMID: 23284065; PubMed Central PMCID: PMC3589244.

### **B.3. Microstructural White Matter Changes in Carriers of the DYT1 Mutation.**

(Carbon et al. 2004b)

This study was the very first DTI study in dystonia. The aim of this study was to test the hypothesis that the DYT1 genotype was associated with a disorder of micro-anatomical connectivity as a consequence of a neurodevelopmental disruption. At the time of the study this hypothesis was based (1) on the clinical observation of the typical age of onset in DYT1 dystonia during childhood or adolescence, a time of intense synaptic pruning (Bressman 2004), (2) on the early notion of a role for the nematode homologue of torsinA in cytoskeletal dynamics (Basham and Rose 2001; Ferrari Toninelli et al. 2003) and (3) on the lack of functional network expression during learning in asymptomatic mutation carriers (Carbon et al. 2002; for details see B.10., B.11.).

We used DTI on a 1.5 Tesla MRI scanner to assess measures of diffusivity as the basis of diffusion tensor calculation in white matter pathways in 12 DYT1 mutation carriers (age:  $44.1 \pm 17.8$  years) and in 17 age-matched control subjects (age:  $43.3 \pm 17.0$  years). Out of the twelve DYT1 mutation carriers, eight were non-manifesting (age:  $53.4 \pm 13.9$  years) and four were manifesting (age:  $25.5 \pm 17.8$  years). Voxel-based analyses showed FA reductions ( $p < 0.005$ ) in the subgyral white matter of the SMC of DYT1 carriers. Due to the small number of manifesting carriers, no analyses regarding MAN-DYT1 vs. NM-DYT1 were performed.

These results were the first to suggest micro-structural in vivo correlates of genotype specific changes. They also contributed to the discussion of the role of torsinA in neurodevelopment. Interestingly, concomitant to the publication of the results in humans, the molecular role of torsinA was found to relate closely to the nuclear envelope, which in turn has a crucial role in neurodevelopment (Gerace, 2004; Goodchild and Dauer 2004). Subsequently, a line of research has confirmed and expanded the suggested role of torsinA in neurodevelopment. Nery and colleagues (2008) found that mutant torsinA, unlike wild-type torsinA, clustered very strongly with nesprin-3 (a molecule spanning the outer nuclear membrane). They also assessed the orientation of the centrosome relative to the nucleus and the leading edge of dividing cells. In wild type torsinA containing cells the vast majority was correctly polarized. By contrast, mutant torsinA containing cells showed the correct polarization only in around 40% (Nery et al. 2008).

Regarding the work in humans, this study was the basis for a series of subsequent manuscripts, exploring microstructural correlates of symptom manifestation in DYT1 dystonia (Carbon et al. 2008, Argyelan/Carbon et al. 2009, Vo et al. submitted to J Nsci 2013) and in other dystonias (see also C.1.b.).

**p. 35 – 38:**

Carbon M, Kingsley PB, Su S, Smith GS, Spetsieris P, Bressman S, Eidelberg D. Microstructural white matter changes in carriers of the DYT1 gene mutation. *Ann Neurol.* 2004 Aug;56(2):283-6. PubMed PMID: 15293281. DOI: 10.1002/ana.20177



#### **B.4. Microstructural White Matter Changes in Primary Torsion Dystonia.** (Carbon et al., 2008)

Based on the observation of reduced microstructural connectivity in the subgyral white matter of the SMC (Carbon et al. 2004), we aimed to assess whether additional microstructural changes were present within motor control pathways in subjects manifesting with dystonia.

Thus, in this study subjects carrying the DYT1 or the DYT6 mutation were included. Specifically, seven subjects with segmental or generalized dystonia (age:  $29.3 \pm 9.8$  years; four DYT1 and three DYT6 mutation carriers) were compared to seven age-matched controls ( $30.2 \pm 5.8$  years). We used an established DTI protocol at 1.5 Tesla (Lim et al., 1999) and voxel-based analyses to assess the microstructure of white matter.

Measures of FA were significantly reduced in the dystonia patients in the pontine brainstem in the vicinity of the left superior cerebellar peduncle and bilaterally in the white matter of the sensorimotor region. It has to be noted, that the spatial resolution of MRI and as a consequence the projection of statistical maps, as the source of localization of imaging findings is of limited quality in the brainstem. Nevertheless, these findings might be related either to cerebellar outflow pathways as detailed later (Argyelan/Carbon et al. 2009) or to the presence of ubiquitin positive inclusions in the vicinity of the pedunculopontine nucleus (PPN) that had been shown in human manifesting DYT1 carriers (Mc Naught et al., 2004) and in a transgenic mouse model of DYT1 dystonia (Shasidaran et al., 2005). The interpretation of these results is complicated as the PPN cannot be regarded a homogenous structure. It has irregular boundaries and it has particularly long ranging axons, projecting to removed targets, such as the spinal cord or forebrain structures, but it is also closely interrelated with the basal ganglia (Pahapill and Lozano 2000; Martinez-Gonzalez et al., 2011). Ultimately, the observed reductions in brainstem FA were related to the superior cerebellar peduncle, which is the main cerebellar outflow structure (Argyelan/Carbon 2009; B.5.).

**p 40 – 45:**

Carbon M, Kingsley PB, Tang C, Bressman S, Eidelberg D. Microstructural white matter changes in primary torsion dystonia. *Mov Disord*. 2008 Jan 30;23(2):234-9. PubMed PMID: 17999428. DOI 10.1002/mds.21806

## **B.5. Cerebellothalamocortical Connectivity Regulates Penetrance in Dystonia.**

(Argyelan M\*, Carbon M\*, et al., 2009. \*equal author contribution)

The finding of reduced brainstem connectivity in DYT1 and DYT6 dystonia needed to be attributed to a pathway, to understand its functional role within the pathophysiology of dystonia. The DTI studies on the 1.5 Tesla MRI scanner were limited in this regard; a 5 mm skip had been used between each plane during image acquisition to cover the brain volume from vertex to brainstem. Thus vector connections could not be calculated.

The data for this subsequent study were therefore collected at another MRI scanner at 3 Tesla, to enable the use of probabilistic tractography (Behrens et al., 2007). For this study manifesting subjects (n = 12: 7 DYT1/5 DYT6; age  $42.2 \pm 15.2$ ) as well as non-manifesting subjects (n = 8: 4 DYT1/4 DYT6; age  $44.0 \pm 17.4$ ) were recruited. Seed regions for probabilistic tractography were defined based on our earlier DTI studies in the cerebellar outflow pathway. Due to the technical difficulty to calculate vector trajectories past a decussation (Johansen-Berg and Behrens, 2006), two seed masks (for each cerebellar outflow side) were created for each subject; one below and one above the decussation of the cerebellar peduncles. From these seed masks, four individual probabilistic tracts were constructed for each participant. Voxel-based group comparisons of connectivity measures of these tracts revealed reduced integrity of cerebello-thalamo-cortical fiber tracts, in both manifesting and clinically non-manifesting dystonia mutation carriers in the very proximal segment of the superior cerebellar peduncle (Fig. 2 of the amended manuscript). Confirming our earlier observations, these reductions were more pronounced in manifesting than in non-manifesting mutation carriers.

Non-manifesting mutation carriers were additionally distinguished by an area of fiber tract disruption situated distally along the thalamo-cortical segment of the pathway, in tandem with the proximal cerebellar outflow abnormality. Modeling of clinical penetrance showed that in individual gene carriers, clinical penetrance was determined by the difference in connectivity measured at these two sites. In secondary analyses, the functional role of these reductions was explored using correlation analyses of the connectivity measures and brain activation responses recorded during standardized motor tasks with  $H_2^{15}O$  PET (as detailed in chapter B.7). Connectivity measures from a cluster close to the dentate nucleus (see cluster a1 in figure 1 of the amended manuscript) correlated with increased motor activation in the cerebellar nuclei, the thalamus and SMC, consistent with a loss of inhibition at the cortical level.

In summary, the DTI-MRI studies support the idea of hereditary dystonias as neurodevelopmental circuit disorders, rather than the idea of isolated basal ganglia pathology.

**p 47 – 54:**

\*Carbon M; \*Argyelan M, Niethammer M, Ulug AM, Voss HU, Bressman SB, Dhawan V, Eidelberg D. Cerebellothalamocortical connectivity regulates penetrance in dystonia. *J Neurosci*. 2009 Aug 5;29(31):9740-7. doi: 10.1523/JNEUROSCI.2300-09.2009. PubMed PMID: 19657027; PubMed Central PMCID: PMC2745646.

## **B.6. Abnormal Striatal and Thalamic Dopamine Neurotransmission: Genotype-Related Features of Dystonia.** (Carbon et al., 2009)

As highlighted in the general introduction, there is ample evidence to support the idea of a major role of dopaminergic transmission in the dystonias (Burke et al., 1982; Factor and Matthews, 1991; Hierholzer et al.; 1994; Ernst et al., 1996; Wong et al., 1996; Naumann et al.; 1998; Brashear et al., 1999; Casey, 2004; Perlmutter et al., 1997; Kühn et al., 2008). Indeed, a disturbance of the dopaminergic system is the only etiology present in DRD, or in tardive dystonias subsequent to D<sub>2</sub> receptor blocking agent exposure. Nevertheless, earlier studies in primary dystonias had only shown minor changes within the dopaminergic system. In particular, an earlier study in NM-DYT1 (Asanuma et al., 2005), showed a 15% reduction of D<sub>2</sub> receptor binding in caudate and putamen. The present study was performed to assess whether changes in D<sub>2</sub> receptor availability would determine symptom manifestation in carriers of mutations for primary dystonia.

Manifesting and non-manifesting carriers of the DYT1 and DYT6 genotype were scanned with [(11)C] raclopride (RAC) and PET during rest. Measures of D<sub>2</sub> receptor availability in the caudate nucleus and putamen were determined using a standardized region-of-interest approach with explicit age correction (Asanuma et al. 2005). Values from mutation carriers and healthy controls were compared using analysis of variance to assess the effects of genotype and phenotype. Additionally, voxel-based whole brain searches were conducted to detect group differences in extrastriatal regions.

Our data showed significant reductions of caudate and putamen D<sub>2</sub> receptor availability in both genotypes independently compared to healthy controls ( $p < 0.001$ ). The changes were more pronounced in DYT6 than in DYT1 carriers ( $-38.0 \pm 3.0\%$  vs  $-15.0 \pm 3.0\%$ ,  $p < 0.001$ ). Importantly, dopaminergic changes did not relate to symptom manifestation, as there were no differences between manifesting and non-manifesting carriers of either genotype.

Voxel-based analysis additionally revealed reduced RAC binding in the ventrolateral thalamus of both groups of mutation carriers. As in the striatum, the thalamic binding reductions were more pronounced in DYT6 carriers and were not influenced by the presence of clinical manifestations.

In human hereditary dystonia, it is possible that the reduced D<sub>2</sub> receptor availability results from (1) dysfunction of D<sub>2</sub>-bearing neurons, (2) or loss of D<sub>2</sub>-bearing neurons, (3) increased synaptic dopamine levels, or (4) a combination of the mechanisms. These changes, which may be present to different degrees in the DYT1 and DYT6 genotypes, are likely to represent only one aspect of the susceptibility factors in mutation carriers. Consistent with limited clinical efficacy of dopamine depleting agents in these genotypes, a salient role of the dopaminergic system in disease control can likely be dismissed.

**p 56 – 62:**

Carbon M, Niethammer M, Peng S, Raymond D, Dhawan V, Chaly T, Ma Y, Bressman S, Eidelberg D. Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia. *Neurology*. 2009 Jun 16;72(24):2097-103. doi: 10.1212/WNL.0b013e3181aa538f. PubMed PMID: 19528516; PubMed Central PMCID: PMC2697963.

## **B.7. Increased Sensorimotor Network Activity in DYT1 Dystonia: a Functional Imaging Study.** (Carbon et al., 2010)

Neurophysiological studies have provided evidence of a loss of inhibition at the level of the primary motor cortex in primary dystonia, but data from functional imaging studies in primary dystonia are highly contradictory (see chapter A.2.c./d.).

To address this problem on a systems level, we measured sensorimotor activation during a paced, kinematically controlled motor task (Ghilardi et al., 2000) with H<sub>2</sub><sup>15</sup>O PET in DYT1 mutation carriers (11 MAN-DYT1 predominantly with generalized dystonia, age: 42.8 ± 15.5 years and 10 NM-DYT1, age: 51.5 ± 14.3 years) and in age-matched controls (n=12; age: 44.7 ± 12.7 years). Imaging data and behavioral data were obtained and analyzed in this study.

The motor task consisted in reaching regularly for eight circularly arrayed targets on a digitizing tablet in a counter clockwise manner (target array as detailed in Figure 4; **B.8**). This task can be performed even in the presence of dystonia and movement kinematics are recorded during the task to enable movement analyses and correlation of motor characteristics with brain activation measures. Importantly, the control condition did not consist of complete resting, but was matched with regard to the audio-visual input to the motor task. This had been designed to clearly isolate motor related activation as opposed the sensory input related to the standardized task. Within- and between-group contrasts were analyzed with SPM 5. For network analysis, we used ordinal trends analysis (Habeck et al., 2005) and first identified a normal motor-related activation pattern (NMRP) in a set of 39 motor and audio-visual scans acquired in an independent cohort of 18 healthy volunteer subjects. Ordinal trends analysis is a supervised principal components analysis technique designed to identify spatial covariance patterns that change in expression within individual subjects across experimental conditions. The expression of this pattern was then prospectively quantified in the motor and control scans acquired in each of the gene carriers and controls, using automated prospective network calculation. Network values for controls, NM-DYT1 and MAN-DYT1 were compared with ANOVA and post hoc contrasts.

Voxel-wise comparison of DYT1 carriers and controls revealed abnormally increased motor activation responses ( $P < 0.05$ , corrected in SPM), in the SMC, dorsal PreMC, SMA and the inferior parietal cortex. Network analysis of the normative derivation cohort identified the normal motor-related activation pattern topography (i.e the covariant network activity that showed a significant increase from rest to motor activation in all subject,  $P < 0.0001$ ; NMRP). This NMRP was characterized by covarying neural activity in the SMC, dorsal PreMC, SMA and cerebellum (Figure 2 in the amended manuscript). In the DYT1 study cohort, prospective

network calculation showed that NMRP expression during movement was abnormally elevated in the MAN-DYT1 ( $P < 0.001$ ) but not in NM-DYT1 (Figure 3 in the amended manuscript). In contrast, in the non-motor control condition, abnormal increases in NMRP network activity were present in both groups of gene carriers ( $P < 0.001$ ). In this condition, NMRP expression in non-manifesting carriers was greater than in controls, but lower than in affected carriers (Figure 3 in the amended manuscript). Importantly, NMRP expression in the audio-visual condition correlated with independent dystonia clinical ratings ( $r = 0.70$ ,  $P = 0.04$ ).

In addition to the image analysis, kinematic data were analyzed: As expected, general motor task performance, expressed as the percentage of correctly hit targets, was reduced in MAN-DYT1 ( $49.4 \pm 11.4\%$ , mean  $\pm$  SD) compared to controls as well as to their non-manifesting counterparts (controls:  $85.1 \pm 7.2\%$ ; non-manifesting DYT1:  $77.4 \pm 4.8$ ;  $p=0.004$ ). Moreover, dystonics showed a greater movement irregularity of the repetitive reaching movements, expressed as a higher individual standard deviation of movement time (defined as the time from movement onset to the end point for an individual reaching movement to one target; movement time\_SD: MAN-DYT1:  $103.6 \pm 9.0\text{ms}$ ; NM-DYT1:  $69.7 \pm 11.3$ ; controls:  $60.5 \pm 12.0\text{ms}$ ;  $P = 0.003$ ). All other motor kinematics did not differ significantly from controls. Importantly, no abnormalities of motor kinematics were recorded in the NM-DYT1 group.

As mentioned above (Chapter B.5), there was a close correlation of functional motor abnormalities (i.e. SMC and PreMC activation) and microstructural abnormalities within the cerebellar outflow pathway. This association was also confirmed in the reverse approach: In an auxiliary analysis, we used measures of NMRP during the AV condition as covariates for FA maps in nine DYT1 mutation carriers. Whole brain voxel-based analyses disclosed a significant negative correlation in the dorsal brainstem in vicinity of cerebellar outflow pathways ( $R^2 = 0.82$   $p=0.006$ ).

Conversely, we also studied associations of measures of  $D_2$  receptor availability obtained in earlier studies (cf. chapter B.6), however, neither NMRP expression, nor behavioral motor kinematic characteristics were correlated with either measures of caudate or putamen  $D_2$  receptor availability ( $R < 0.2$ ;  $p > 0.2$  for all analyses).



**p. 65 – 75:**


Carbon M, Argyelan M, Habeck C, Ghilardi MF, Fitzpatrick T, Dhawan V, Pourfar M, Bressman SB, Eidelberg D. Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. *Brain*. 2010 Mar;133(Pt 3):690-700. doi: 10.1093/brain/awq017. Epub 2010 Mar 5. PubMed PMID: 20207699; PubMed Central PMCID: PMC2842516.

## B.8. Increased Cerebellar Activation during Sequence Learning in DYT1

### Carriers: an Equiprobability Study. (Carbon et al., 2008b).

Sequence learning experiments have long been established as probes for basal ganglia function (for review see Hikosaka et al., 1999; Hardwick et al., 2013), and have thus been of interest for studies in movement disorders.

For the purpose of this study sequence learning-related network activation was first established in health (Ghilardi et al., 2000; Carbon et al. 2003) and the modulation of this network activity was tested in Parkinson's disease ON and OFF treatment (Nakamura et al., 2001 Carbon et al. 2003).



In these tasks (detailed in Ghilardi et al., 2000) the hand path for the reaching movements was recorded on a digitizing tablet. For the simple motor task (see figure 4) subjects had to reach for the serially highlighting targets at a pace of 1/s (enforced by a tone sounding in the same rhythm). The targets were highlighted in counterclockwise order in a predictable manner, so subjects could plan the movement and perform the reaching in a rhythmical way to arrive at the target in the correct time frame (signaled to the subject by a change in color of the target). By contrast, for the motor sequence learning task (MSEQ; using the same target array, see figure 4) eight targets per cycle were highlighted in an unpredictable, but repetitive manner. The subjects had to try to reach for the target within the correct time frame (1/ s as in the simple motor task), making this task a reaction time task for the first cycle of the target appearances. During the repeating cycles though, subjects achieved explicit and implicit knowledge of target positions and sequences could thus progressively be learned. Subjects were instructed that a repeating pattern of eight targets was to be learnt. Any target that was reached in an anticipatory manner (i.e. movement onset was recorded before target appearance) counted as a learnt target. The sum of all correctly anticipated movements

during one trial block was termed the global retrieval index. An additional learning index, the acquisition index was also defined: Any correctly hit target that had not been successfully anticipated in the previous cycled counted an acquired target.

Having established the normal acquisition and retrieval networks in health and in PD (Carbon et al. 2003), we expected to find a similar modification of networks in hereditary dystonia, since this was considered mostly a basal ganglia disorder. However, neither the acquisition network, nor the retrieval network was expressed in DYT1 mutation carriers (Carbon et al., 2004d, 2007). Instead, increased cerebellar recruitment was recorded, both at the network level (Carbon et al. 2007) as well as measured in voxel-based group comparisons (Ghilardi et al., 2003; Carbon et al., 2008, 2011).

Group comparisons during sequence in NM-DYT1 vs. controls found that despite comparable motor performance, sequence learning in MSEQ was reduced in NM-DYT1 relative to age-matched controls (Ghilardi et al., 2003). During sequence learning, activation responses in DYT1 carriers were increased in the left ventral PFC cortex, and lateral cerebellum. These findings suggested that abnormalities in sensorimotor integration and brain function exist in NM-DYT1, and that these manifest as defect in motor sequence learning.

In addition to the univariate group comparisons (Ghilardi et al., 2003), network analyses (as detailed above) were used in this dataset to test for normal network expression in DYT1 mutation carriers (Carbon et al., 2002; Carbon et al., 2004d). Surprisingly, and in stark contrast to PD (as detailed in chapter B.8), network-performance relationships were absent in NM-DYT1. Instead a DYT1 specific network was identified, characterized by covarying motor sequence learning specific activation in the SMC, DLPFC, anterior cerebellar cortex and cerebellar dentate nucleus. Contrasting to healthy controls there was no contribution of the basal ganglia in the DYT1 specific network, and there was a stronger contribution of the cerebellum (Carbon et al., 2002). As this cerebellar shift was absent in the neurodegenerative disorder, we hypothesized that an early neurodevelopmental process might relate to cerebellar shift during learning in the DYT1 genotype.

In the subsequent study (Carbon et al., 2008b) we used a modified version of the earlier sequence learning task MSEQ. In this task the targets appearing in the same target array as detailed above were not presented sequentially, but were to be discovered by trial-and-error. We chose to alter the task, because trial and error learning depends strongly on cerebellar input (Doya 2000). Moreover, this trial-and-error sequence-learning task (TSEQ) could be adapted in difficulty to match the mutation carrier group and controls to the same level of performance (i.e. controls perform subjectively easy tasks, which can then be matched to the

performance level of the disease group). An equiperformance study design (c.f. Mentis et al., 2003) is suited to identify neural resources that are used to achieve performance within the normal range. Six NM-DYT1 and six control subjects were scanned with H<sub>2</sub><sup>15</sup>O PET during TSEQ and a matched motor execution task. PET data analysis was performed using SPM99.

Although performing at matched levels, NM-DYT1 overactivated the lateral cerebellum and the right inferotemporal cortex relative to age-matched controls. In contrast, they showed relative activation deficits in DLPFC bilaterally, as well as in the left anterior cingulate and the dorsal premotor cortex.

The prominent compensatory involvement of the cerebellum during target learning confirmed our earlier results in NM-DYT1 (Ghilardi et al., 2003; Carbon et al., 2004d.). Contrasting to mutation carriers, normals used bilateral cerebellar activation in conjunction with a prominent prefrontal bilateralization when confronted with a much higher task difficulty. That means, that this compensatory cerebellar activation could be interpreted as a normal sign of adaptive cerebral plasticity. However, as (1) dystonia has been related to abnormally increased plasticity on many levels (Quartarone et al. 2006) and (2) dystonia has been linked to cerebellar pathology (LeDoux 2003), we suggested that this cerebellar overactivation reflects a maladaptive neuroplastic response.

**p. 79 -87:**

Carbon M, Ghilardi MF, Argyelan M, Dhawan V, Bressman SB, Eidelberg D. Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study. *Brain*. 2008 Jan;131(Pt 1):146-54. Epub 2007 Oct 18. PubMed PMID: 17947338. doi: 10.1093/brain/awm243

## **B.9. Impaired Sequence Learning in Dystonia Mutation Carriers: a Genotypic**

**Effect.** (Carbon et al., 2011)

We expanded the observations in NM-DYT1 to MAN DYT1 to explore the effect of genotype and phenotype in sequence learning abnormalities. In the current study, we assessed whether sequence learning deficits were also present in clinically manifesting DYT1 carriers or carriers of other primary dystonia mutations such as the DYT6 genotype. Additionally, we determined whether sequence learning performance and associated brain activation in these subjects correlate with previously described genotype-related abnormalities of cerebellar pathway integrity (as detailed in chapter B. 5) and striatal D2 dopamine receptor binding (as detailed in chapter B.6). Nineteen DYT1 carriers (10 NM DYT1; age:  $51.5 \pm 15.1$  years; nine MAN DYT1; age:  $46.1 \pm 15.1$  years) and 12 healthy control subjects (age:  $42.8 \pm 15.3$  years) were scanned with  $H_2^{15}O$  PET while performing the motor sequence learning task MSEQ and an observational sequence learning task (VSEQ) as well as respectively matched reference tasks (as detailed in chapter B.8). Eleven DYT6 carriers (four NM-DYT6: age  $38.0 \pm 22.1$  years; seven manifesting DYT6:  $35.3 \pm 14.2$  years) were evaluated during task performance without concurrent PET imaging. Subgroups of DYT1 and DYT6 carriers also underwent DTI MRI and  $^{11}C$ -raclopride PET to measure caudate/putamen  $D_2$  receptor binding. These imaging measures were correlated with sequence learning performance and associated activation responses.

There was no effect of symptom manifestation on sequence learning performance. Sequence learning deficits of similar magnitude were observed in MAN-DYT1 and NM-DYT1. Importantly, however, despite major similarities in microstructural abnormalities, learning deficits were not detected in DYT6 carriers, irrespective of clinical penetrance. Voxel-based image analyses (SPM 5) showed significant increases in sequence learning-related activation in the left lateral cerebellar cortex and in the right premotor and inferior parietal regions in MAN-DYT1 relative to controls. Increases in premotor cortical activation observed in the mutation carriers correlated with reductions in cerebellar pathway integrity measured using magnetic resonance diffusion tensor imaging and probabilistic tractography. Additionally, the cerebellar tract changes correlated with reductions in dentate nucleus activation recorded during task performance. By contrast, sequence learning performance and task-related activation responses did not correlate with striatal  $D_2$  receptor binding, even though a close relationship between these measures had been shown in an earlier study in controls and in early unmedicated Parkinson's disease patients (Carbon et al. 2004c).

The role of the cerebellum in modulating neocortical activation is a current topic of research, in particular, the mechanism by which cerebellum and cortex interact during learning in health, warrant further investigation (Koziol et al. 2013; Bostan et al. 2013). A deeper

understanding of these mechanisms would enable a more informed interpretation of our findings in DYT1 dystonia.

In summary, we found that sequence learning deficits and concomitant increases in cerebellar activation are specific features of the DYT1 genotype. The close relationship between reduced cerebellar pathway integrity and increased learning-related activation of the premotor cortex is compatible with the view of DYT1 dystonia as a neurodevelopmental circuit disorder.

**p. 90 – 101:**

Carbon M, Argyelan M, Ghilardi MF, Mattis P, Dhawan V, Bressman S, Eidelberg D. Impaired sequence learning in dystonia mutation carriers: a genotypic effect. *Brain*. 2011 May;134 (Pt 5):1416-27. doi: 10.1093/brain/awr060. Epub 2011 Apr 22. PubMed PMID: 21515903; PubMed Central PMCID: PMC3097890.



## **C. DISCUSSION**

Using a multi-modal imaging approach in hereditary dystonias, this series of studies supported the overarching hypotheses, showing that metabolic, microstructural, functional changes reach well beyond an isolated affection of the indirect striatal pathway, as suggested for hyperkinetic disorders traditionally (Albin et al., 1989). Similarly, a predominant role of dopaminergic neurotransmission within the basal ganglia was dismissed as hypothesized.

We demonstrated that functional changes of the striatum, both at the metabolic and the neurochemical level reflect the susceptibility for primary torsion dystonia (Carbon et al., 2004a, Carbon et al., 2009, Carbon et al., 2011). By contrast, penetrance and disease severity did not relate to striatal characteristics, but were rather associated with the expression of a cortical sensorimotor brain activation network (Carbon et al., 2011). Importantly, microstructural abnormalities underlying the expression of the cortical sensorimotor network were found in the cerebellar outflow pathways in dystonia mutation carriers (Carbon et al. 2008a; Argyelan/Carbon et al., 2009). Interestingly, we found a novel interaction of cerebello-thalamic and thalamo-cortical connectivity as a potential mechanism regulating penetrance in the DYT1 and DYT6 genotype (Argyelan/Carbon et al., 2009). Thus, our data suggest that the functional entity of sensorimotor circuitry rather than one node within this network regulates symptom expression in dystonia.

### **C.1. Metabolic and Microstructural Changes**

The results of our studies have shed additional light on the disturbance of neural circuitry and the abnormal structure/function relationships that characterize dystonia. Localization of circuit changes adds to the discussion on new therapeutic targets and treatment strategies for this disorder. Unfortunately, rather than supporting the idea of a prevailing, unifying pathology for the hereditary dystonias, the FDG-studies (Carbon et al., 2004a, 2013) have demonstrated striking disparities of brain glucose metabolism between hereditary dystonias. The DYT1 genotype is characterized by striatal and cerebellar metabolic increases, whereas metabolic reductions in the same areas are found in the DYT6 genotype. Moreover, conjunction analyses across all genotypes assessed (Carbon et al., 2013) identified only a small region within the parietal association cortices as a shared metabolic feature of dystonia.

In summary, three major elements emerge from the line of work on metabolism and microstructure in hereditary dystonias: (1) cerebellar abnormalities (in addition to striatal

changes), (2) microstructural abnormalities within cerebello-thalamo-cortical circuits (3) parietal cortex abnormalities.

### ***C.1.a. Cerebellar Abnormalities***

While abnormal inferior cerebellar cortex hypermetabolism primarily characterized susceptibility in DYT1 dystonia (Carbon et al., 2004a), network analyses showed an interaction of trait and state features with relative cerebellar hypometabolism within the DYT1 and DYT6 genotype (Carbon and Eidelberg, 2006, 2009).

By contrast, within the DYT11 genotype, parasagittal cerebellar hypermetabolism was found to be related to symptom expression. Importantly, however, this region was likely more related to the presence of myoclonus, as it was a shared characteristic with posthypoxic myoclonus and the shared abnormality with dystonia was localized to the parietal cortex (Carbon et al., 2013).

The results from DYT1 positive humans have since been tested in a transgenic DYT1 knock-in mouse model (Ulug et al., 2011). Heterozygous knock-in mice and littermate controls underwent microPET followed by ex vivo high-field DTI and tractographic analysis. As detailed in the introduction (A.2.b) these mutant mice fail to develop clinical correlates of dystonia or other abnormal movements. Nevertheless, the DYT1 knock-in mice showed significant cerebello-thalamo-cortical tract changes and abnormalities in brainstem regions linking cerebellar and basal ganglia motor circuits, clearly similar to the abnormalities identified earlier in humans (Carbon et al., 2008a, Argyelan et al., 2009). In addition, as in humans, measures of SMC activity (metabolic measures in mice, as opposed to activation induced blood flow in humans) were associated with connectivity measures from cerebello-thalamo-cortical circuits (Ulug et al., 2011). In conclusion, these results reflect the human pathology and demonstrate that DYT1 mutant torsinA has similar effects in mice and humans despite the absence of overt motor pathology in the animal model.

Similarly, our results have stimulated further studies in mice, which overexpress mutant human torsinA (hMT1). These studies have elaborated on the cerebellar abnormalities found in our studies (Zhao et al., 2011): Using a combination of cytochrome oxidase histochemistry and 2-deoxyglucose autoradiography, high spatial resolution of metabolic activity can be obtained ex vivo. As in our studies, the authors demonstrated a shift of metabolic demand from the basal ganglia to the cerebellum in the hMT1 mouse (Zhao et al., 2011). Detailing on these findings, they were able to localize the abnormal metabolism to the Purkinje cell layer and the molecular layer of the cerebellum. In this mouse model, increased metabolic activity was also noted in the inferior olive, which sends excitatory input to cerebellar Purkinje cells via the climbing fiber pathway. Thus the altered Purkinje metabolism may be interpreted as a

consequence of olivary input change resulting in a change of firing properties of Purkinje cells (Zhao et al., 2011).

In another study the morphological cerebellar features were studied in *DYT1*  $\Delta$ GAG knock-in (KI) mice (Zhang et al., 2011). These transgenic mice were found to have reduced lengths of primary dendrites and a decrease in the number of spines on the distal dendrites of Purkinje cells. In a further specification, mice with a knockout restricted to the *DYT1* gene only in Purkinje cells were created (to exclude the possibility of adaptive changes in other brain regions). In these mice similar alterations in Purkinje cell morphology were found, confirming the idea of inherent cerebellar pathology rather than adaptive changes as consequences of basal ganglia alteration.

The normal function of torsinA is a continued topic of discussion. TorsinA is expressed throughout the brain, but with particularly high levels in dopaminergic neurons of the substantia nigra and in the deep cerebellar nuclei (Shashidharan et al., 2000), and with regard to the temporal pattern in particular during phases of intense neurodevelopment (Siegert et al. 2005; Vasudevan et al., 2006; McCarthy et al., 2012). Thus, these regions are prone to be affected by mutant torsinA dysfunction, particularly during periods of synaptogenesis, such as during cerebral maturation in childhood or adolescence. The cerebellar distribution of torsinA during juvenile neurodevelopment has been further detailed (Puglisi et al., 2013), showing that this protein is highly expressed in cerebellar nuclei as well as in the cerebellar cortex. The expression on Purkinje cells was characterized by a striking involvement of the dendrites and spines, but other cerebellar cortical cells also expressed this protein. Moreover, specific analyses showed that afferent projections to the cerebellar cortex, in particular GABA-ergic and glutamergic synaptic contacts and glial cells also expressed high levels of torsinA (Puglisi et al., 2013). These findings highlight the broad functional involvement of the mutated protein in *DYT1* dystonia, and reflect the molecular basis of the observed changes in cerebellar metabolism and function.

While the back-transfer from “bedside-to-bench” may seem counterintuitive, it is important to note that accepted animal models of dystonia are sorely needed for drug screening purposes. In the current situation, where animal models either fail to reproduce abnormal movements, or fail to reflect human pathology, it is particularly meaningful when parallels of human pathology and animal pathology can be demonstrated. In this vein the analogies of findings detailed above, highlight an important step towards the development of a generally accepted animal model of dystonia.

Contrasting to the *DYT1* genotype, relatively few studies have focused on the function of THAP1, where mutations are found in the *DYT6* genotype. THAP1 was found to be transcribed in the cerebral cortex, cerebellum, striatum, substantia nigra, thalamus and spinal cord (Zhao et al., 2013); importantly the highest expression of THAP1 was found during the

early neurodevelopment in the cerebellum (Zhao et al., 2013). As with torsinA, cerebellar Purkinje cells expressed THAP1, but the protein was also found in cortical pyramidal cells, thalamic relay nuclei, medium spiny and cholinergic neurons in the striatum as well as in dopaminergic neurons in the substantia nigra. This observation lends further support to the concept of hereditary dystonia as a neurodevelopmental disorder involving the cerebellum as a major component of neurocircuitry. In addition, this expression is in line with our observation of a more pronounced involvement of the striatal dopaminergic system (cf. B.6.) in the DYT6 genotype.

The role of the cerebellum has increasingly been recognized during the period of this series of studies (partly supported by the impact of our studies). A major contribution to this discussion was the work by Neychev and colleagues (2008), who implemented a series of experimental animal models to show the functional interaction the cerebellum and basal ganglia in the expression of dystonic symptoms. It was only later, that a direct anatomical connection of these structures was described using retrograde transneuronal virus transport labeling (Bostan et al., 2010). The recent acceptance of models including cerebellar contributions to mechanisms of dystonia is illustrated by the increasing number of reviews, which have devoted the focus to cerebellar abnormalities in human dystonia (Jinnah and Hess 2006; Avazino and Abbruzzese 2012, Sadnicka et al. 2012, Filip et al. 2013)

### ***C.1.b. Neurodevelopmental Abnormalities***

The major contribution of this line of work to dystonia research is the conceptual framework of dystonia as neurodevelopmental circuit disorder (Carbon et al., 2004b, Ozelius et al., 2011). Our early finding of abnormal sensorimotor network connectivity in NM-DYT1 (Carbon et al. 2004b) has since been corroborated and expanded in independent human studies in sporadic focal dystonias (Blood et al. 2006, 2012; Bonilha et al., 2007, 2009; Delmaire et al. 2007, 2009) and in DYT6 dystonia (Cheng et al., 2012), which showed widespread changes throughout all elements of the sensorimotor circuits

Importantly, the suggestion of DYT1 dystonia as a neurodevelopmental disorder related to abnormalities of cytoskeletal dynamics, as posited in our studies (e.g. Carbon et al., 2004b), is increasingly supported (Nery et al., 2008) and has sparked research in animal models. In co-immune precipitation studies, Hewett and colleagues (2006) found an association between vimentin and torsinA in one complex including other cytoskeletal elements. Overexpression of mutant torsinA inhibited neurite extension in human neuroblastoma cells, with torsinA and vimentin immunoreactivity enriched in the perinuclear region and in cytoplasmic inclusions. The molecular underpinnings of neurodevelopmental effects of torsinA mutations have also been explored in a study on neurogenesis and neuronal

migration of the embryonic forebrain in a torsinA knock-out mouse (McCarthy et al., 2012), which showed subtle, but significant alterations in neuronal migration.

Recently, DYT4 dystonia has been linked to a missense mutation within the gene  $\beta$ -tubulin 4a, which codes for an autoregulatory domain of  $\beta$ -tubulin (Hersheson et al., 2012). Since tubulin is the fundamental element of microtubules, this finding provides yet another link for a role of the cytoskeleton in dystonia pathogenesis. Importantly,  $\beta$ -tubulin 4a is brain specific with highest expression in the cerebellum, followed by the putamen.

### ***C.1.c. Parietal Abnormalities***

Throughout all of our studies, we found abnormal metabolism and activation in the parietal cortex in the dystonias (Ghilardi et al., 2003; Carbon et al., 2004a, 2013, 2011, 2010). This area showed increased metabolism in manifesting as opposed to non-manifesting DYT1 and DYT6 mutation carriers (Carbon et al., 2004a). Moreover, this area showed the only overlapping metabolic abnormality in different hereditary dystonias (Carbon et al., 2013). A dysfunction of this region was also noted in the DYT1 genotype during repetitive reaching (Ghilardi et al., 2003) and during visual or motor sequence learning (Carbon et al., 2011). It is likely that both of these features are interrelated, even though metabolic values do not correlate with measures of learning performance. In a broader scope, it is rather likely that parietal abnormalities also contribute to those somatosensory integration deficits that have been repeatedly described in the dystonias (Tinazzi et al., 2009).

The posterior parietal cortex serves somatosensory integration (Xing and Andersen, 2000; Hsiao 2008) and the role of somatosensory perception and integration is increasingly recognized in dystonia (Konczak and Abbruzzese 2013; Quartarone and Hallett 2013). While a broader spectrum of somatosensory integration or perception abnormalities have been reported in sporadic focal dystonias (Tinazzi et al., 2009), deficient temporal discrimination has been reported in DYT1 dystonia (Fiorio et al., 2007). Affected and non-affected DYT1 mutation carriers showed a significantly reduced ability to temporally discriminate tactile-tactile or tactile-visual stimulation pairs. Moreover, affected DYT1 mutation carriers showed impaired temporal visual-visual discrimination, indicating a continuum of genotype to phenotype relation. The posterior parietal metabolic abnormalities as observed in our studies may give rise to somatosensory integration deficits, as this region has been shown to be active during sensory temporal order judgment tasks in healthy subjects (Nakashita et al., 2008; Lewandowska et al., 2010; Takahashi et al., 2013).

Parietal dysfunction in dystonia has also been demonstrated in other imaging studies (Elbert et al., 1998; Sanger et al., 2002; Butterworth et al., 2003; Dolberg et al., 2011; Dresel et al., 2011; Opavsky et al. 2011; Delnooz et al., 2012; Moore et al., 2012; Tinazzi et al., 2013), but

the integration of these findings into the concept of dystonia is an ongoing debate. Nevertheless, there are treatment approaches, at least for task induced focal dystonias addressing the somatosensory integration abnormalities in dystonia (e.g. Candia et al., 2003).

Moreover, linking the parietal abnormalities back to abnormal cerebellar function, widespread direct cerebellar-cortical connections have now been clearly demonstrated, and importantly so, these involve strong interactions with the posterior parietal cortex (Bostan, et al., 2013).

## **C.2. Neurochemical Changes in Dystonia**

### ***C.2.a. The Dopaminergic System***

Our studies indicated that subtle changes in dopaminergic neurotransmission are present in DYT1 and more so in DYT6 dystonia. However, these were genotypic changes and unlikely to account for symptoms of DYT1 or DYT6 dystonia (Asanuma et al., 2005; Carbon et al., 2009). This lack of a symptomatic effect points to the causal potential of other neurotransmitter systems in DYT1 and DYT6 dystonia (such as e.g. cholinergic neurotransmission). Whether or not symptoms in sporadic dystonias are causally related to the dopaminergic systems remains to be determined in future research.

Our observations are in line with observations in animal models of DYT1 dystonia, which have found increased striatal dopa-decarboxylase (DOPAC) and homovanilinic acid (HVA) levels pointing to an increased dopamine turnover (Zhao et al., 2008; Page et al., 2010). By contrast, another study in a transgenic mouse model (with human mutant DYT1) showed a reduced amount of striatal D<sub>2</sub> receptor protein (Napolitano et al., 2010). Importantly, these animal studies pinpoint reasons for the reduced D<sub>2</sub> receptor availability that could not have been demonstrated in humans. Increased dopamine turnover can be demonstrated by amphetamine stimulation paradigms (e.g. Laruelle et al., 1996), but the use of amphetamine in dystonia is discouraged due to its potential to provoke or worsen dystonia (e.g. Thiel and Dressler, 1994; Priori et al., 1995).

It is important to recognize the genotypic or etiological differences of dystonias, as in other dystonias, such as DRD, tardive dystonia or levodopa induced dystonias, the dopaminergic system is clearly involved in symptom expression. By contrast, while dopaminergic modulation is therapeutically effective in these dystonias, a focus on other systems may be needed in other genotypes.

### ***C.2.b. Perspective into Changes in Striatal Acetylcholine***

Given that the dopaminergic system is unlikely to represent the key factor in at least DYT1 and DYT6 dystonia, the cholinergic system is a likely, but clearly under-researched contributor to mechanisms of disease in hereditary dystonias. One of the most effective therapies for these disorders, particularly during childhood and adolescence, is anticholinergic medication. Thus, abnormal cholinergic striatal function has been considered (Augood et al., 2002), but in-vivo evidence is limited for technical reasons. Moreover, cholinergic and dopaminergic striatal functions are so intricately interrelated, that both a direct defect within the cholinergic system or an indirect dysfunction of the cholinergic system due to (slight) dopaminergic dysfunction, or a combination of both could cause dystonia (Pisani et al., 2006). Long-term synaptic adaptations at cortico-striatal and thalamo-striatal synapses represent the basis of sensorimotor integration; and modulation of these depends on striatal cholinergic interneuron contacts with striatal medium spiny neurons (Calabresi et al., 2000). In turn, these cholinergic interneurons are dependent on nigrostriatal dopaminergic input (Aosaki et al., 1995). As a consequence, a loss of this dopaminergic input would lead to an increased excitability of cholinergic interneurons, with subsequent defective modulation of abnormal sensorimotor integration, as seen in dystonia. This intricate linking of cholinergic and dopaminergic abnormalities has been demonstrated in a series of current studies in a DYT1 mutant mouse model (Pisani et al. 2006, Martella et al., 2009; Sciamanna et al., 2012a,b).

### **C.3 Abnormal Network Activation in Dystonia**

Our activation studies mainly focused on motor activation and sequence learning tasks. For these studies, the respective normal network topography was characterized first and network-performance relationships were calculated next (Carbon et al., 2003, 2010). Then, in a next step network expression was quantified in the disease state using prospective network calculation (Carbon et al. 2004d, 2010). Using this technique, we found consistently, that DYT1 and DYT6 mutation carriers do not show the same patterns of neuronal interregional connectivity that healthy controls showed (Carbon et al., 2010a, 2010b). This finding contrasts with findings in Parkinson's disease, in which despite the degenerative nature of the disease, normal network- performance relationships exist (Carbon et al., 2003). In Parkinson's disease these networks have even been demonstrated to be modulated with antiparkinsonian interventions (Carbon et al., 2003).

Decreased intracortical inhibition and abnormal cortical plasticity are consistent, shared features of sporadic and hereditary dystonias, but they have not yet been clearly linked to an underlying abnormality (Quartarone et al., 2006; Edwards et al., 2006). Although it is possible that these features relate to intracortical microcircuitry abnormalities, the widespread

changes found throughout all elements of the sensorimotor circuits in dystonia suggest a role of interregional neuronal relationships in the formation of these cortical abnormalities. In this vein, abnormal measures of structural connectivity have indeed also been demonstrated in sporadic dystonia (Delmaire et al., 2009; Bonilha et al., 2007, 2008; Blood et al., 2006). Whether or not the functional changes found in sporadic dystonia relate to altered structure-function relationships is elusive. As detailed above, for hereditary dystonias our line of work has shown a relationship of functional and structural networks.

Few external studies have addressed functional networks in dystonia: Moore and colleagues (2012) used motor studies with individuated finger control during f-MRI in task specific dystonia. They analyzed the data with a different network analysis technique, psychophysiological interactions modeling, where seed volumes of interest are defined to identify individual task-dependent changes in functional connectivity between the defined volume of interest and the remaining brain. They found *increased* functional connectivity of the posterior (sensorimotor) putamen with the cerebellum and SMC as well as *increased* connectivity of the anterior (associative) putamen with SMA, the left PreMC, and left cerebellum. Similar results were reported in a resting state f-MRI study in writer's cramp (Mohammadi et al., 2012), which analyzed data with independent component analysis (i.e. hypothesis free covariation analysis, similar to our approach). In addition to increased basal ganglia connectivity, these authors reported reduced somatosensory cortex connectivity. Another resting-state f-MRI study in cervical dystonia (Delnooz et al., 2012) study found reduced connectivity within the sensorimotor network.

While it is possible that sporadic and hereditary dystonias show different abnormalities, in the same way as primary and secondary dystonia have been demonstrated to differ with regard to cortical plasticity (Kojovic et al., 2013), it is more likely, that differences in study design contribute strongly to seemingly contrasting results. F-MRI studies rely inherently on image subtraction techniques; thus baseline (group or task) differences often confound these studies.

In summary, our studies support the concept of dystonia as a motor circuitry disorder with a prominent role of cerebellar pathways in DYT1 and DYT6 dystonia (Carbon et al., 2004a; 2008c; Argyelan/Carbon et al., 2009). We propose that these dystonias result from a fundamental neurodevelopmental disturbance leading to anatomical/functional disconnection at the cerebellar level. Indeed, maldevelopment of cerebellar output pathways is a likely cause for the localized metabolic abnormalities seen in the resting state (Eidelberg et al., 1998; Trost et al., 2001; Carbon and Eidelberg, 2009) as well as those seen during motor and learning tasks (Ghilardi et al., 2003; Carbon et al. 2004d, 2008b, 2010a, 2011; Carbon and Eidelberg 2009).



## LITERATURE

Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: A consensus update. *Mov Disord*. 2013 May 6. doi: 10.1002/mds.25475. [Epub ahead of print]

Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. *Trends Neurosci*. 1989 Oct;12(10):366-75.

Alexander GE and Moeller JR. Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: A principal component approach to modeling brain function in disease. *Human Brain Mapping* 1994; 2: 1-16.

Almasy L, Bressman SB, Raymond D, Kramer PL, Greene PE, Heiman GA, Ford B, Yount J, de Leon D, Chouinard S, Saunders-Pullman R, Brin MF, Kapoor RP, Jones AC, Shen H, Fahn S, Risch NJ, Nygaard TG. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. *Ann Neurol*. 1997 Oct;42(4):670-3.

Aosaki T, Kimura M, Graybiel AM. Temporal and spatial characteristics of tonically active neurons of the primate's striatum. *J Neurophysiol*. 1995 Mar;73(3):1234-52

Argyelan M, Carbon M, Niethammer M, Ulug AM, Voss HU, Bressman SB, Dhawan V, Eidelberg D. Cerebellothalamocortical connectivity regulates penetrance in dystonia. *J Neurosci*. 2009 Aug 5;29(31):9740-7.

Asanuma K, Ma Y, Huang C, Carbon-Correll M, Edwards C, Raymond D, Bressman SB, Moeller JR, Eidelberg D. The metabolic pathology of dopa-responsive dystonia. *Ann Neurol*. 2005 Apr;57(4):596-600.

Asanuma K, Ma Y, Okulski J, Dhawan V, Chaly T, Carbon M, Bressman SB, Eidelberg D. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. *Neurology*. 2005 Jan 25;64(2):347-9.

Augood SJ, Hollingsworth Z, Albers DS, Yang L, Leung JC, Muller B, Klein C, Breakefield XO, Standaert DG. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. *Neurology*. 2002 Aug 13;59(3):445-8.

Avanzino L, Abbruzzese G. How does the cerebellum contribute to the pathophysiology of dystonia. *Basal Ganglia*. 2012 (2);4.231–235.

Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, Standaert DG. Dopamine release is impaired in a mouse model of DYT1 dystonia. *J Neurochem*. 2007 Aug;102(3):783-8.

Basham SE, Rose LS. The *Caenorhabditis elegans* polarity gene *ooc-5* encodes a Torsin-related protein of the AAA ATPase superfamily. *Development*. 2001 Nov;128(22):4645-56.

Battista AF, Goldstein M, Miyamoto T, Matsumoto Y. Effect of centrally acting drugs on experimental torticollis in monkeys. *Adv Neurol*. 1976;14:329-38.

Behrens TE, Berg HJ, Jbabdi S, Rushworth MF, Woolrich MW. Probabilistic diffusion tractography with multiple fibre orientations: What can we gain? *Neuroimage*. 2007 Jan 1;34(1):144-55.

Beukers RJ, Foncke EM, van der Meer JN, Nederveen AJ, de Ruyter MB, Bour LJ, Veltman DJ, Tijssen MA. Disorganized sensorimotor integration in mutation-positive myoclonus-dystonia: a functional magnetic resonance imaging study. *Arch Neurol*. 2010 Apr;67(4):469-74.

Beukers RJ, Foncke EM, van der Meer JN, Veltman DJ, Tijssen MA. Functional magnetic resonance imaging evidence of incomplete maternal imprinting in myoclonus-dystonia. *Arch Neurol*. 2011 Jun;68(6):802-5.

Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. *Brain*. 1994 Aug;117 ( Pt 4):859-76.

Black KJ, Ongür D, Perlmutter JS. Putamen volume in idiopathic focal dystonia. *Neurology*. 1998 Sep;51(3):819-24.

Blood AJ, Kuster JK, Woodman SC, Kirlic N, Makhlof ML, Multhaupt-Buell TJ, Makris N, Parent M, Sudarsky LR, Sjalander G, Breiter H, Breiter HC, Sharma N. Evidence for altered basal ganglia-brainstem connections in cervical dystonia. *PLoS One*. 2012;7(2):e31654. doi: 10.1371/journal.pone.0031654.

Blood AJ, Tuch DS, Makris N, Makhlof ML, Sudarsky LR, Sharma N. White matter abnormalities in dystonia normalize after botulinum toxin treatment. *Neuroreport*. 2006 Aug 21;17(12):1251-5.

Bomar JM, Benke PJ, Slattery EL, Puttagunta R, Taylor LP, Seong E, Nystuen A, Chen W, Albin RL, Patel PD, Kittles RA, Sheffield VC, Burmeister M. Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. *Nat Genet*. 2003 Nov;35(3):264-9.

Bonilha L, de Vries PM, Vincent DJ, Rorden C, Morgan PS, Hurd MW, Besenski N, Bergmann KJ, Hinson VK. Structural white matter abnormalities in patients with idiopathic dystonia. *Mov Disord*. 2007 Jun 15;22(8):1110-6.

Bonilha L, de Vries PM, Hurd MW, Rorden C, Morgan PS, Besenski N, Bergmann KJ, Hinson VK. Disrupted thalamic prefrontal pathways in patients with idiopathic dystonia. *Parkinsonism Relat Disord*. 2009 Jan;15(1):64-7.

Bostan AC, Dum RP, Strick PL. The basal ganglia communicate with the cerebellum. *Proc Natl Acad Sci U S A*. 2010 May 4;107(18):8452-6.

Bostan AC, Dum RP, Strick PL. Cerebellar networks with the cerebral cortex and basal ganglia. *Trends Cogn Sci*. 2013 May;17(5):241-54.

Brashear A, Mulholland GK, Zheng QH, Farlow MR, Siemers ER, Hutchins GD. PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). *Mov Disord*. 1999 Jan;14(1):132-7.

Braun C, Schweizer R, Heinz U, Wiech K, Birbaumer N, Topka H. Task-specific plasticity of somatosensory cortex in patients with writer's cramp. *Neuroimage*. 2003 Oct;20(2):1329-38

Bressman SB, de Leon D, Kramer PL, Ozelius LJ, Brin MF, Greene PE, Fahn S, Breakefield XO, Risch NJ. Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. *Ann Neurol*. 1994 Nov;36(5):771-7.

Bressman SB. Dystonia genotypes, phenotypes, and classification. *Adv Neurol*. 2004;94:101-7.

Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. *Neurology*. 1982 Dec;32(12):1335-46.

Butterworth S, Francis S, Kelly E, McGlone F, Bowtell R, Sawle GV. Abnormal cortical sensory activation in dystonia: an fMRI study. *Mov Disord*. 2003 Jun;18(6):673-82.

Byl NN, Merzenich MM, Jenkins WM. A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex in adult monkeys. *Neurology*. 1996 Aug;47(2):508-20.

Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Acetylcholine-mediated modulation of striatal function. *Trends Neurosci*. 2000 Mar;23(3):120-6.

Candia V, Wienbruch C, Elbert T, Rockstroh B, Ray W. Effective behavioral treatment of focal hand dystonia in musicians alters somatosensory cortical organization. *Proc Natl Acad Sci U S A*. 2003 Jun 24;100(13):7942-6.

Carbon M., Ghilardi MF, Dhawan F, Eidelberg D. Brain networks subserving motor sequence learning in DYT1 gene carriers. *Neurology* 2002; 58(7):A203.

Carbon M, Ghilardi MF, Feigin A, Fukuda M, Silvestri G, Mentis MJ, Ghez C, Moeller JR, Eidelberg D. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. *Hum Brain Mapp*. 2003 Jul;19(3):197-211.

Carbon M, Su S, Dhawan V, Raymond D, Bressman S, Eidelberg D. Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. *Neurology*. 2004a Apr 27;62(8):1384-90.

Carbon M, Kingsley PB, Su S, Smith GS, Spetsieris P, Bressman S, Eidelberg D. Microstructural white matter changes in carriers of the DYT1 gene mutation. *Ann Neurol*. 2004b Aug;56(2):283-6.

Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. *Neuroimage*. 2004c Apr;21(4):1497-507.

Carbon M, Trost M, Ghilardi MF, Eidelberg D. Abnormal brain networks in primary torsion dystonia. *Adv Neurol*. 2004d;94:155-61.

Carbon M, Eidelberg D. Functional imaging of sequence learning in Parkinson's disease. *J Neurol Sci*. 2006 Oct 25;248(1-2):72-7

Carbon M., Feigin A., Eidelberg D. Multivariate analysis: Applications to the study of hereditary movement disorders. *Clinical Neuroscience Research* 2007 (6): 375-380.

Carbon M, Kingsley PB, Tang C, Bressman S, Eidelberg D. Microstructural white matter changes in primary torsion dystonia. *Mov Disord*. 2008a Jan 30;23(2):234-9.

Carbon M, Ghilardi MF, Argyelan M, Dhawan V, Bressman SB, Eidelberg D. Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study. *Brain*. 2008b Jan;131 (Pt 1):146-54.

Carbon M, Ozelius LJ, Raymond D, Bressman S, Eidelberg D. Metabolic correlates of genetic susceptibility in DYT-1 torsion dystonia. *Neurology* 2008c; 70:A43.

Carbon M, Niethammer M, Peng S, Raymond D, Dhawan V, Chaly T, Ma Y, Bressman S, Eidelberg D. Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia. *Neurology*. 2009 Jun 16;72(24):2097-103.

Carbon M, Eidelberg D. Abnormal structure-function relationships in hereditary dystonia. *Neuroscience*. 2009 Nov 24;164(1):220-9.

Carbon M, Argyelan M, Habeck C, Ghilardi MF, Fitzpatrick T, Dhawan V, Pourfar M, Bressman SB, Eidelberg D. Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. *Brain*. 2010a Mar;133(Pt 3):690-700.

Carbon M, Reetz K, Ghilardi MF, Dhawan V, Eidelberg D. Early Parkinson's disease: longitudinal changes in brain activity during sequence learning. *Neurobiol Dis*. 2010c Feb;37(2):455-60.

Carbon M, Argyelan M, Ghilardi MF, Mattis P, Dhawan V, Bressman S, Eidelberg D. Impaired sequence learning in dystonia mutation carriers: a genotypic effect. *Brain*. 2011 May;134(Pt 5):1416-27.

Carbon M, Raymond D, Ozelius L, Saunders-Pullman R, Frucht S, Dhawan V, Bressman S, Eidelberg D. Metabolic changes in DYT11 myoclonus-dystonia. *Neurology*. 2013 Jan 22;80(4):385-91.

Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. *J Clin Psychiatry*. 2004;65 Suppl 9:25-8.

Ceballos-Baumann AO, Passingham RE, Marsden CD, Brooks DJ. Motor reorganization in acquired hemidystonia. *Ann Neurol*. 1995a Jun;37(6):746-57.

Ceballos-Baumann AO, Passingham RE, Warner T, Playford ED, Marsden CD, Brooks DJ. Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia. *Ann Neurol*. 1995b Mar;37(3):363-72.

Ceballos-Baumann AO, Sheean G, Passingham RE, Marsden CD, Brooks DJ. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. *Brain*. 1997 Apr;120 (Pt 4):571-82.

Chen CC, Kühn AA, Hoffmann KT, Kupsch A, Schneider GH, Trottenberg T, Krauss JK, Wöhrle JC, Bardinet E, Yelnik J, Brown P. Oscillatory pallidal local field potential activity correlates with involuntary EMG in dystonia. *Neurology*. 2006. Feb 14;66(3):418-20.

Cheng FB, Wan XH, Feng JC, Ma LY, Hou B, Feng F, Wang L, Yang YM. Subcellular distribution of THAP1 and alterations in the microstructure of brain white matter in DYT6 dystonia. *Parkinsonism Relat Disord*. 2012 Sep;18(8):978-82.

Chiken S, Shashidharan P, Nambu A. Cortically evoked long-lasting inhibition of pallidal neurons in a transgenic mouse model of dystonia. *J Neurosci*. 2008 Dec 17;28(51):13967-77.

Classen J. Focal hand dystonia--a disorder of neuroplasticity? *Brain*. 2003 Dec;126(Pt 12):2571-2.

Dang MT, Yokoi F, McNaught KS, Jengelley TA, Jackson T, Li J, Li Y. Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia. *Exp Neurol*. 2005 Dec;196(2):452-63.

Dang MT, Yokoi F, Pence MA, Li Y. Motor deficits and hyperactivity in Dyt1 knockdown mice. *Neurosci Res*. 2006 Dec;56(4):470-4

Davies W, Isles AR, Wilkinson LS. Imprinted gene expression in the brain. *Neurosci Biobehav Rev* 2005;29:421-430.

de Carvalho Aguiar PM, Ozelius LJ. Classification and genetics of dystonia. *Lancet Neurol*. 2002 Sep;1(5):316-25.

Delmaire C, Vidailhet M, Elbaz A, Bourdain F, Bleton JP, Sangla S, Meunier S, Terrier A, Lehericy S. Structural abnormalities in the cerebellum and sensorimotor circuit in writer's cramp. *Neurology*. 2007 Jul 24;69(4):376-80.

Delmaire C, Vidailhet M, Wassermann D, Descoteaux M, Valabregue R, Bourdain F, Lenglet C, Sangla S, Terrier A, Deriche R, Lehericy S. Diffusion abnormalities in the primary sensorimotor pathways in writer's cramp. *Arch Neurol*. 2009 Apr;66(4):502-8.

Delnooz CC, Helmich RC, Toni I, van de Warrenburg BP. Reduced parietal connectivity with a premotor writing area in writer's cramp. *Mov Disord*. 2012 Sep 15;27(11):1425-31.

Delnooz CC, Pasma JW, Beckmann CF, van de Warrenburg BP. Task-free functional MRI in cervical dystonia reveals multi-network changes that partially normalize with botulinum toxin. *PLoS One*. 2013 May 1;8(5):e62877.

Detante O, Vercueil L, Thobois S, Broussolle E, Costes N, Lavenne F, Chabardes S, Lebars D, Vidailhet M, Benabid AL, Pollak P. Globus pallidus internus stimulation in primary generalized dystonia: a H215O PET study. *Brain*. 2004;127:1899-908.

Dhawan V, Kazumata K, Robeson W, Belakhlef A, Margouleff C, Chaly T, Nakamura T, Dahl R, Margouleff D, and Eidelberg D. Quantitative brain PET: Comparison of 2D and 3D acquisition on the GE Advance Scanner. *Clinical Positron Imaging* 1998; 1(2): 135-144

Di Lazzaro V, Oliviero A, Profice P, Dileone M, Pilato F, Insola A, Della Marca G, Tonali PA, Mazzone P. Reduced cerebral cortex inhibition in dystonia: direct evidence in humans. *Clin Neurophysiol*. 2009 Apr;120(4):834-9.

Dolberg R, Hinkley LB, Honma S, Zhu Z, Findlay AM, Byl NN, Nagarajan SS. Amplitude and timing of somatosensory cortex activity in task-specific focal hand dystonia. *Clin Neurophysiol*. 2011 Dec;122(12):2441-51.

- Doya K. Complementary roles of basal ganglia and cerebellum in learning and motor control. *Curr Opin Neurobiol.* 2000 Dec;10(6):732-9.
- Draganski B, Thun-Hohenstein C, Bogdahn U, Winkler J, May A. "Motor circuit" gray matter changes in idiopathic cervical dystonia. *Neurology.* 2003 Nov 11;61(9):1228-31.
- Draganski B, Schneider SA, Fiorio M, Klöppel S, Gambarin M, Tinazzi M, Ashburner J, Bhatia KP, Frackowiak RS. Genotype-phenotype interactions in primary dystonias revealed by differential changes in brain structure. *Neuroimage.* 2009 Oct 1;47(4):1141-7.
- Dresel C, Bayer F, Castrop F, Rimpau C, Zimmer C, Haslinger B. Botulinum toxin modulates basal ganglia but not deficient somatosensory activation in orofacial dystonia. *Mov Disord.* 2011 Jul;26(8):1496-502.
- Edwards MJ, Huang YZ, Mir P, Rothwell JC, Bhatia KP. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. *Mov Disord.* 2006 Dec;21(12):2181-6.
- Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Przedborski S, Fahn S. The metabolic topography of idiopathic torsion dystonia. *Brain.* 1995 Dec;118 ( Pt 6):1473-84.
- Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, Dhawan V, Spetsieris P, deLeon D, Bressman SB, Fahn S. Functional brain networks in DYT1 dystonia. *Ann Neurol.* 1998 Sep;44(3):303-12.
- Elbert T, Candia V, Altenmüller E, Rau H, Sterr A, Rockstroh B, Pantev C, Taub E. Alteration of digital representations in somatosensory cortex in focal hand dystonia. *Neuroreport.* 1998 Nov 16;9(16):3571-5.
- Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Hardy K, Hankerson JG, Doudet DJ, Cohen RM. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. *N Engl J Med.* 1996 Jun 13;334(24):1568-72
- Esmaeli-Gutstein B, Nahmias C, Thompson M, Kazdan M, Harvey J. Positron emission tomography in patients with benign essential blepharospasm. *Ophthal Plast Reconstr Surg.* 1999 Jan;15(1):23-7.
- Factor SA, Matthews MK. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. *South Med J.* 1991 May;84(5):626-8.
- Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S, eds. *Movement disorders 2.* London: Butterworths; 1987:332–358.
- Feiwell RJ, Black KJ, McGee-Minnich LA, Snyder AZ, MacLeod AM, Perlmutter JS. Diminished regional cerebral blood flow response to vibration in patients with blepharospasm. *Neurology.* 1999 Jan 15;52(2):291-7.
- Ferrari Toninelli G, Spano P, Memo M, TorsinA, microtubules and cell polarity. *Funct Neurol.* 2003 Jan-Mar;18(1):7-10
- Filip P, Lungu OV, Bareš M. Dystonia and the cerebellum: a new field of interest in movement disorders? *Clin Neurophysiol.* 2013 Jul;124(7):1269-76.

Fiorio M, Gambarin M, Valente EM, Liberini P, Loi M, Cossu G, Moretto G, Bhatia KP, Defazio G, Aglioti SM, Fiaschi A, Tinazzi M. Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia? *Brain*. 2007 Jan;130(Pt 1):134-42.

Foltz EL, Knopp LM, Ward AA Jr. Experimental spasmodic torticollis. *J Neurosurg*. 1959 Jan;16(1):55-67.

Fuchs T, Gavarini S, Saunders-Pullman R, Raymond D, Ehrlich ME, Bressman SB, Ozelius LJ. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. *Nat Genet*. 2009 Mar;41(3):286-8.

Fuller J, Prescott IA, Moro E, Toda H, Lozano A, Hutchison WD. Pallidal deep brain stimulation for a case of hemidystonia secondary to a striatal stroke. *Stereotact Funct Neurosurg*. 2013;91(3):190-7

Furukawa Y, Hornykiewicz O, Fahn S, Kish SJ. Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. *Neurology*. 2000 Mar 14;54(5):1193-5.

Garraux G, Bauer A, Hanakawa T, Wu T, Kansaku K, Hallett M. Changes in brain anatomy in focal hand dystonia. *Ann Neurol*. 2004 May;55(5):736-9.

Gerace L. TorsinA and torsion dystonia: Unraveling the architecture of the nuclear envelope. *Proc Natl Acad Sci U S A*. 2004 Jun 15;101(24):8839-40.

Ghilardi M, Ghez C, Dhawan V, Moeller J, Mentis M, Nakamura T, Antonini A, Eidelberg D. Patterns of regional brain activation associated with different forms of motor learning. *Brain Res*. 2000 Jul 14;871(1):127-45.

Ghilardi MF, Carbon M, Silvestri G, Dhawan V, Tagliati M, Bressman S, Ghez C, Eidelberg D. Impaired sequence learning in carriers of the DYT1 dystonia mutation. *Ann Neurol*. 2003 Jul;54(1):102-9.

Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. *Proc Natl Acad Sci U S A*. 2004 Jan 20;101(3):847-52. Epub 2004 Jan 7.

Guyot MC, Hantraye P, Dolan R, Palfi S, Mazière M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. *Neuroscience*. 1997 Jul;79(1):45-56.

Habeck C, Krakauer JW, Ghez C, Sackeim HA, Eidelberg D, Stern Y, and Moeller JR. A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. *Neural Comput* 2005; 17(7): 1602-1645

Hallett M. Neurophysiology of dystonia: The role of inhibition. *Neurobiol Dis*. 2011 May;42(2):177-84.

Hardwick RM, Rottschy C, Miall RC, Eickhoff SB. A quantitative meta-analysis and review of motor learning in the human brain. *Neuroimage*. 2013 Feb 15;67:283-97.

Herath P, Gallea C, van der Veen JW, Horovitz SG, Hallett M. In vivo neurochemistry of primary focal hand dystonia: a magnetic resonance spectroscopic neurometabolite profiling study at 3T. *Mov Disord*. 2010 Dec 15;25(16):2800-8.

Hersheson J, Mencacci NE, Davis M, Macdonald N, Trabzuni D, Ryten M, Pittman A, Paudel R, Kara E, Fawcett K, Plagnol V, Bhatia KP, Medlar AJ, Stanescu HC, Hardy J, Kleita R, Wood NW, Houlden H. Mutations in the autoregulatory domain of  $\beta$ -tubulin 4a cause hereditary dystonia. *Ann Neurol*. 2012 Dec 13. doi:10.1002/ana.23832. [Epub ahead of print]

Hewett JW, Zeng J, Niland BP, Bragg DC, Breakefield XO. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. *Neurobiol Dis*. 2006 Apr;22(1):98-111.

Hierholzer J, Cordes M, Schelosky L, Richter W, Keske U, Venz S, Semmler W, Poewe W, Felix R. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. *J Nucl Med*. 1994 Dec;35(12):1921-7.

Hikosaka O, Nakahara H, Rand MK, Sakai K, Lu X, Nakamura K, Miyachi S, Doya K. Parallel neural networks for learning sequential procedures. *Trends Neurosci*. 1999 Oct;22(10):464-71.

Hornykiewicz O, Kish SJ, Becker LE, Farley I, Shannak K. Brain neurotransmitters in dystonia musculorum deformans. *N Engl J Med*. 1986 Aug 7;315(6):347-53.

Hoshi E, Tremblay L, Féger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. *Nat Neurosci*. 2005 Nov;8(11):1491-3.

Hsiao S. Central mechanisms of tactile shape perception. *Curr Opin Neurobiol*. 2008 Aug;18(4):418-24.

Hubsch C, Vidailhet M, Rivaud-Pechoux S, et al. Impaired saccadic adaptation in DYT11 dystonia. *J Neurol Neurosurg Psychiatry* 2011;82:1103–1106

Hudson QJ, Kulinski TM, Huetter SP, Barlow DP. Genomic imprinting mechanisms in embryonic and extraembryonic mouse tissues. *Heredity* 2010;105:45–56.

Hutchinson M, Nakamura T, Moeller JR, Antonini A, Belakhlef A, Dhawan V, Eidelberg D. The metabolic topography of essential blepharospasm: a focal dystonia with general implications. *Neurology*. 2000 Sep 12;55(5):673-7.

Ibáñez V, Sadato N, Karp B, Deiber MP, Hallett M. Deficient activation of the motor cortical network in patients with writer's cramp. *Neurology*. 1999 Jul 13;53(1):96-105

Ichinose H, Suzuki T, Inagaki H, Ohye T, Nagatsu T. Molecular genetics of dopa-responsive dystonia. *Biol Chem*. 1999 Dec;380(12):1355-64.

Jankovic J. Treatment of hyperkinetic movement disorders. *Lancet Neurol*. 2009 Sep;8(9):844-56. doi: 10.1016/S1474-4422(09)70183-8.

Jinnah HA, Hess EJ. A new twist on the anatomy of dystonia: the basal ganglia and the cerebellum? *Neurology*. 2006 Nov 28;67(10):1740-1.

Jinnah H, Richter A, Mink JW, Caldwell GA, Caldwell KA, Gonzalez-Alegre P, Cookson MR, Breakefield XO, DeLong MR, Hess EJ. Animal models for drug discovery in dystonia. *Expert Opin Drug Discov*. 2008 Jan;3(1):83-97.



Johansen-Berg H, Behrens TE. Just pretty pictures? What diffusion tractography can add in clinical neuroscience. *Curr Opin Neurol*. 2006 Aug;19(4):379-85.

Kerrison JB, Lancaster JL, Zamarripa FE, Richardson LA, Morrison JC, Holck DE, Andreason KW, Blaydon SM, Fox PT. Positron emission tomography scanning in essential blepharospasm. *Am J Ophthalmol*. 2003 Nov;136(5):846-52.

Kock N, Naismith TV, Boston HE, Ozelius LJ, Corey DP, Breakefield XO, Hanson PI. Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. *Hum Mol Genet*. 2006 Apr 15;15(8):1355-64.

Kojovic M, Pareés I, Kassavetis P, Palomar FJ, Mir P, Teo JT, Cordivari C, Rothwell JC, Bhatia KP, Edwards MJ. Secondary and primary dystonia: pathophysiological differences. *Brain*. 2013 Jul;136(Pt 7):2038-49.

Konczak J, Abbruzzese G. Focal dystonia in musicians: linking motor symptoms to somatosensory dysfunction. *Front Hum Neurosci*. 2013 Jun 25;7:297.

Koziol LF, Budding D, Andreasen N, D'Arrigo S, Bulgheroni S, Imamizu H, Ito M, Manto M, Marvel C, Parker K, Pezzulo G, Ramnani N, Riva D, Schmahmann J, Vandervert L, Yamazaki T. Consensus Paper: The Cerebellum's Role in Movement and Cognition. *Cerebellum*. 2013 Aug 31. [Epub ahead of print]

Kühn AA, Brücke C, Schneider GH, Trottenberg T, Kivi A, Kupsch A, Capelle HH, Krauss JK, Brown P. Increased beta activity in dystonia patients after drug-induced dopamine deficiency. *Exp Neurol*. 2008 Nov;214(1):140-3.

Kumar R, Dagher A, Hutchison WD, Lang AE, Lozano AM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. *Neurology*. 1999 Sep 11;53(4):871-4.

Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. *Proc Natl Acad Sci U S A*. 1996 Aug 20;93(17):9235-40.

LeDoux MS, Lorden JF, Meinzen-Derr J. Selective elimination of cerebellar output in the genetically dystonic rat. *Brain Res*. 1995 Oct 30;697(1-2):91-103.

LeDoux MS, Brady KA. Secondary cervical dystonia associated with structural lesions of the central nervous system. *Mov Disord*. 2003 Jan;18(1):60-9.

LeDoux MS. Animal models of dystonia: Lessons from a mutant rat. *Neurobiol Dis*. 2011 May;42(2):152-61.

Lerner A, Shill H, Hanakawa T, Bushara K, Goldfine A, Hallett M. Regional cerebral blood flow correlates of the severity of writer's cramp symptoms. *Neuroimage*. 2004 Mar;21(3):904-13.

Levy LM, Hallett M. Impaired brain GABA in focal dystonia. *Ann Neurol*. 2002 Jan;51(1):93-101.

Lewandowska M, Piatkowska-Janko E, Bogorodzki P, Wolak T, Szelag E. Changes in fMRI BOLD response to increasing and decreasing task difficulty during auditory perception of temporal order. *Neurobiol Learn Mem.* 2010 Oct;94(3):382-91.

Lorden JF, McKeon TW, Baker HJ, Cox N, Walkley SU. Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans. *J Neurosci.* 1984 Aug;4(8):1925-32.

Lorden JF, Lutes J, Michela VL, Ervin J. Abnormal cerebellar output in rats with an inherited movement disorder. *Exp Neurol.* 1992 Oct;118(1):95-104.

Magyar-Lehmann S, Antonini A, Roelcke U, Maguire RP, Missimer J, Meyer M, Leenders KL. Cerebral glucose metabolism in patients with spasmodic torticollis. *Mov Disord.* 1997 Sep;12(5):704-8.

Martella G, Tassone A, Sciamanna G, Platania P, Cuomo D, Viscomi MT, Bonsi P, Cacci E, Biagioni S, Usiello A, Bernardi G, Sharma N, Standaert DG, Pisani A. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. *Brain.* 2009 Sep;132(Pt9):2336-49.

Martinez-Gonzalez C, Bolam JP, Mena-Segovia J. Topographical organization of the pedunculo-pontine nucleus. *Front Neuroanat.* 2011 Apr 5;5:22.

McCarthy DM, Gioioso V, Zhang X, Sharma N, Bhide PG. Neurogenesis and neuronal migration in the forebrain of the TorsinA knockout mouse embryo. *Dev Neurosci.* 2012;34(4):366-78.

McKeon TW, Lorden JF, Oltmans GA, Beales M, Walkley SU. Decreased catalepsy response to haloperidol in the genetically dystonic (dt) rat. *Brain Res.* 1984 Aug 6;308(1):89-96.

McNaught KS, Kapustin A, Jackson T, Jengelle TA, Jnobaptiste R, Shashidharan P, Perl DP, Pasik P, Olanow CW. Brainstem pathology in DYT1 primary torsion dystonia. *Ann Neurol.* 2004 Oct;56(4):540-7.

Mentis MJ, Dhawan V, Feigin A, Delalot D, Zgaljardic D, Edwards C, Eidelberg D. Early stage Parkinson's disease patients and normal volunteers: comparative mechanisms of sequence learning. *Hum Brain Mapp.* 2003b Dec;20(4):246-58.

Miyake H. Spasmodic torticollis-like posture and caudate nucleus monoamine in cats: in vivo dialysis study. *Neurol Res.* 1988 Dec;10(4):213-6.

Moeller JR, Habeck C. Reciprocal benefits of mass-univariate and multivariate modeling in brain mapping: Applications to event-related functional MRI, H215O and PET, *Int J Biomed Imaging.* 2006. Article ID 79862, pages 1-13.

Mohammadi B, Kollwe K, Samii A, Beckmann CF, Dengler R, Münte TF. Changes in resting-state brain networks in writer's cramp. *Hum Brain Mapp.* 2012 Apr;33(4):840-8.

Moore RD, Gallea C, Horovitz SG, Hallett M. Individuated finger control in focal hand dystonia: an fMRI study. *Neuroimage.* 2012 Jul 16;61(4):823-31.

Mori K, Shimabukuro H, Yamashiro K, Miyake H, Kawano T. Spasmodic head movements produced by destruction of unilateral ventromedial tegmentum in cats. *Appl Neurophysiol.* 1985;48(1-6):347-50.

Müller B, Hedrich K, Kock N, et al. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. *Am J Hum Genet* 2002;71:1303–1311.

Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W; Austrian Botulinum Toxin and Dystonia Study Group. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. *J Neurol.* 2002 Jul;249(7):842-6.

Nakamura T, Ghilardi MF, Mentis M, Dhawan V, Fukuda M, Hacking A, Moeller JR, Ghez C, Eidelberg D. Functional networks in motor sequence learning: abnormal topographies in Parkinson's disease. *Hum Brain Mapp.* 2001 Jan;12(1):42-60.

Nakashita S, Saito DN, Kochiyama T, Honda M, Tanabe HC, Sadato N. Tactile-visual integration in the posterior parietal cortex: a functional magnetic resonance imaging study. *Brain Res Bull.* 2008 Mar 28;75(5):513-25.

Nambu A, Chiken S, Shashidharan P, Nishibayashi H, Ogura M, Kakishita K, Tanaka S, Tachibana Y, Kita H, Itakura T. Reduced pallidal output causes dystonia. *Front Syst Neurosci.* 2011 Nov 28;5:89.

Napolitano F, Pasqualetti M, Usiello A, Santini E, Pacini G, Sciamanna G, Errico F, Tassone A, Di Dato V, Martella G, Cuomo D, Fisone G, Bernardi G, Mandolesi G, Mercuri NB, Standaert DG, Pisani A. Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. *Neurobiol Dis.* 2010 Jun;38(3):434-45

Naumann M, Pirker W, Reiners K, Lange KW, Becker G, Brücke T. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [<sup>123</sup>I] epidepride and [<sup>123</sup>I] beta-CIT. *Mov Disord.* 1998 Mar;13(2):319-23.

Neumann WJ, Huebl J, Brücke C, Ruiz MH, Kupsch A, Schneider GH, Kühn AA. Enhanced low-frequency oscillatory activity of the subthalamic nucleus in a patient with dystonia. *Mov Disord.* 2012 Jul;27(8):1063-6.

Nery FC, Zeng J, Niland BP, Hewett J, Farley J, Irimia D, Li Y, Wiche G, Sonnenberg A, Breakefield XO. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. *J Cell Sci.* 2008 Oct 15;121(Pt 20):3476-86.

Neychev VK, Fan X, Mitev VI, Hess EJ, Jinnah HA. The basal ganglia and cerebellum interact in the expression of dystonic movement. *Brain.* 2008 Sep;131(Pt 9):2499-509.

Nishibayashi H, Ogura M, Kakishita K, Tanaka S, Tachibana Y, Nambu A, Kita H, Itakura T. Cortically evoked responses of human pallidal neurons recorded during stereotactic neurosurgery. *Mov Disord.* 2011 Feb 15;26(3):469-76.

Nitschke MF, Erdmann C, Trillenber P, Sprenger A, Kock N, Sperner J, Klein C. Functional MRI reveals activation of a subcortical network in a 5-year-old girl with genetically confirmed myoclonus-dystonia. *Neuropediatrics.* 2006 Apr;37(2):79-82.

Nobrega JN, Richter A, Burnham WM, Löscher W. Alterations in the brain GABAA/benzodiazepine receptor-chloride ionophore complex in a genetic model of paroxysmal dystonia: a quantitative autoradiographic analysis. *Neuroscience*. 1995 Jan;64(1):229-39.

Nutt JG, Muentner MD, Aronson A, Kurland LT, Melton LJ 3rd. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. *Mov Disord*. 1988;3(3):188-94.

Odergren T, Stone-Elander S, Ingvar M. Cerebral and cerebellar activation in correlation to the action-induced dystonia in writer's cramp. *Mov Disord*. 1998 May;13(3):497-508.

Oga T, Honda M, Toma K, Murase N, Okada T, Hanakawa T, Sawamoto N, Nagamine T, Konishi J, Fukuyama H, Kaji R, Shibasaki H. Abnormal cortical mechanisms of voluntary muscle relaxation in patients with writer's cramp: an fMRI study. *Brain*. 2002 Apr;125(Pt 4):895-903.

Opavský R, Hlušík P, Otruba P, Kaňovský P. Sensorimotor network in cervical dystonia and the effect of botulinum toxin treatment: a functional MRI study. *J Neurol Sci*. 2011 Jul 15;306(1-2):71-5.

Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. *Nat Genet*. 1997 Sep;17(1):40-8.

Ozelius LJ, Lubarr N, Bressman SB. Milestones in dystonia. *Mov Disord*. 2011 May;26(6):1106-26. doi: 10.1002/mds.23775

Page ME, Bao L, Andre P, Pelta-Heller J, Sluzas E, Gonzalez-Alegre P, Bogush A, Khan LE, Iacovitti L, Rice ME, Ehrlich ME. Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. *Neurobiol Dis*. 2010 Sep;39(3):318-26.

Pahapill PA, Lozano AM. The pedunculo-pontine nucleus and Parkinson's disease. *Brain*. 2000 Sep;123 ( Pt 9):1767-83.

Peller M, Zeuner KE, Munchau A, Quartarone A, Weiss M, Knutzen A, Hallett M, Deuschl G, Siebner HR. The basal ganglia are hyperactive during the discrimination of tactile stimuli in writer's cramp. *Brain*. 2006 Oct;129(Pt10):2697-708.

Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, Moerlein SM. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. *J Neurosci*. 1997 Jan 15;17(2):843-50.

Petrucci S, Valente EM. Genetic issues in the diagnosis of dystonias. *Front Neurol*. 2013 Apr 10;4:34. doi: 10.3389/fneur.2013.00034.

Piras G, El Kharroubi A, Kozlov S, et al. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. *Mol Cell Biol* 2000;20:3308–3315

Pisani A, Martella G, Tscherter A, Bonsi P, Sharma N, Bernardi G, Standaert DG. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. *Neurobiol Dis*. 2006 Nov;24(2):318-25.

- Pizoli CE, Jinnah HA, Billingsley ML, Hess EJ. Abnormal cerebellar signaling induces dystonia in mice. *J Neurosci*. 2002 Sep 1;22(17):7825-33.
- Playford ED, Fletcher NA, Sawle GV, Marsden CD, Brooks DJ. Striatal [18F]dopa uptake in familial idiopathic dystonia. *Brain*. 1993 Oct;116 ( Pt 5):1191-9.
- Playford ED, Passingham RE, Marsden CD, Brooks DJ. Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. *Mov Disord*. 1998 Mar;13(2):309-18.
- Preibisch C, Berg D, Hofmann E, Solymosi L, Naumann M. Cerebral activation patterns in patients with writer's cramp: a functional magnetic resonance imaging study. *J Neurol*. 2001 Jan;248(1):10-7.
- Priori A, Bertolasi L, Berardelli A, Manfredi M. Acute dystonic reaction to ecstasy. *Mov Disord*. 1995 May;10(3):353.
- Puglisi F, Vanni V, Ponterio G, Tassone A, Sciamanna G, Bonsi P, Pisani A, Mandolesi G. Torsin A Localization in the Mouse Cerebellar Synaptic Circuitry. *PLoS One*. 2013 Jun 19;8(6):e68063. Print 2013. PubMed PMID: 23840813; PubMed Central PMCID: PMC3686744.
- Pujol J, Roset-Llobet J, Rosinés-Cubells D, Deus J, Narberhaus B, Valls-Solé J, Capdevila A, Pascual-Leone A. Brain cortical activation during guitar-induced hand dystonia studied by functional MRI. *Neuroimage*. 2000 Sep;12(3):257-67.
- Quartarone A, Bagnato S, Rizzo V, Siebner HR, Dattola V, Scafari A, Morgante F, Battaglia F, Romano M, Girlanda P. Abnormal associative plasticity of the human motor cortex in writer's cramp. *Brain*. 2003 Dec;126(Pt 12):2586-96.
- Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? *Trends Neurosci*. 2006 Apr;29(4):192-9.
- Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. *Mov Disord*. 2013 Jun 15;28(7):958-67.
- Rostasy K, Augood SJ, Hewett JW, Leung JC, Sasaki H, Ozelius LJ, Ramesh V, Standaert DG, Breakefield XO, Hedreen JC. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. *Neurobiol Dis*. 2003 Feb;12(1):11-24.
- Rothwell J. Transcranial magnetic stimulation as a method for investigating the plasticity of the brain in Parkinson's disease and dystonia. *Parkinsonism Relat Disord*. 2007;13 Suppl 3:S417-20.
- Sadnicka A, Hoffland BS, Bhatia KP, van de Warrenburg BP, Edwards MJ. The cerebellum in dystonia - help or hindrance? *Clin Neurophysiol*. 2012 Jan;123(1):65-70.
- Sambrook MA, Crossman AR, Slater P. Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway. *Exp Neurol*. 1979 Mar;63(3):583-93.
- Sanger TD, Pascual-Leone A, Tarsy D, Schlaug G. Nonlinear sensory cortex response to simultaneous tactile stimuli in writer's cramp. *Mov Disord*. 2002 Jan;17(1):105-11.
- Schicatanò EJ, Basso MA, Evinger C. Animal model explains the origins of the cranial dystonia benign essential blepharospasm. *J Neurophysiol*. 1997 May;77(5):2842-6.

Schmidt KE, Linden DE, Goebel R, Zanella FE, Lanfermann H, Zubcov AA. Striatal activation during blepharospasm revealed by fMRI. *Neurology*. 2003 Jun 10;60(11):1738-43.

Schulz R, Menheniott TR, Woodfine K, Wood AJ, Choi JD, Oakey RJ. Chromosome-wide identification of novel imprinted genes using microarrays and uniparental disomies. *Nucleic Acids Res* 2006;34:e88.

Sciamanna G, Tassone A, Mandolesi G, Puglisi F, Ponterio G, Martella G, Madeo G, Bernardi G, Standaert DG, Bonsi P, Pisani A. Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. *J Neurosci*. 2012a Aug 29;32(35):11991-2004.

Sciamanna G, Hollis R, Ball C, Martella G, Tassone A, Marshall A, Parsons D, Li X, Yokoi F, Zhang L, Li Y, Pisani A, Standaert DG. Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA. *Neurobiol Dis*. 2012b Sep;47(3):416-27.

Shashidharan P, Sandu D, Potla U, Armata IA, Walker RH, McNaught KS, Weisz D, Sreenath T, Brin MF, Olanow CW. Transgenic mouse model of early-onset DYT1 dystonia. *Hum Mol Genet*. 2005 Jan 1;14(1):125-33.

Siebner HR, Filipovic SR, Rowe JB, Cordivari C, Gerschlager W, Rothwell JC, Frackowiak RS, Bhatia KP. Patients with focal arm dystonia have increased sensitivity to slow-frequency repetitive TMS of the dorsal premotor cortex. *Brain*. 2003 Dec;126(Pt 12):2710-25.

Siegert S, Bahn E, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostasy KM. TorsinA expression is detectable in human infants as young as 4 weeks old. *Brain Res Dev Brain Res*. 2005 Jun 9;157(1):19-26.

Silberstein P, Kühn AA, Kupsch A, Trottenberg T, Krauss JK, Wöhrle JC, Mazzone P, Insola A, Di Lazzaro V, Oliviero A, Aziz T, Brown P. Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. *Brain*. 2003 Dec;126(Pt 12):2597-608.

Standaert DG. Update on the pathology of dystonia. *Neurobiol Dis*. 2011 May;42(2):148-51.

Starr PA, Rau GM, Davis V, Marks WJ Jr, Ostrem JL, Simmons D, Lindsey N, Turner RS. Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque. *J Neurophysiol*. 2005 Jun;93(6):3165-76.

Stratton SE, Lorden JF, Mays LE, Oltmans GA. Spontaneous and harmaline-stimulated Purkinje cell activity in rats with a genetic movement disorder. *J Neurosci*. 1988 Sep;8(9):3327-36.

Tai CH, Yen RF, Lin CH, Yen KY, Yip PK, Wu RM, Lee MJ. Focal brain glucose hypermetabolism in myoclonus-dystonia syndrome caused by an epsilon-sarcoglycan gene mutation. *Parkinsonism Relat Disord*. 2009 Sep;15(8):614-6.

Takahashi T, Kansaku K, Wada M, Shibuya S, Kitazawa S. Neural correlates of tactile temporal-order judgment in humans: an fMRI study. *Cereb Cortex*. 2013 Aug;23(8):1952-64

Tanabe LM, Kim CE, Alagem N, Dauer WT. Primary dystonia: molecules and mechanisms. *Nat Rev Neurol*. 2009 Nov;5(11):598-609.

Taniguchi T, Sullivan MJ, Ogawa O, Reeve AE. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. *Proc Natl Acad Sci USA* 1995;92:2159–2163.

Tempel LW, Perlmutter JS. Abnormal vibration-induced cerebral blood flow responses in idiopathic dystonia. *Brain*. 1990 Jun;113 ( Pt 3):691-707.

Thiel A, Dressler D. Dyskinesias possibly induced by norpseudoephedrine. *J Neurol*. 1994 Jan;241(3):167-9.

Thompson VB, Jinnah HA, Hess EJ. Convergent mechanisms in etiologically-diverse dystonias. *Expert Opin Ther Targets*. 2011 Dec;15(12):1387-403.

Tinazzi M, Fiorio M, Fiaschi A, Rothwell JC, Bhatia KP. Sensory functions in dystonia: insights from behavioral studies. *Mov Disord*. 2009 Jul 30;24(10):1427-36.

Tinazzi M, Marotta A, Fasano A, Bove F, Bentivoglio AR, Squintani G, Pozzer L, Fiorio M. Aristotle's illusion reveals interdigit functional somatosensory alterations in focal hand dystonia. *Brain*. 2013 Mar;136(Pt 3):782-9.

Trost M, Carbon M, Edwards C, Ma Y, Raymond D, Mentis MJ, Moeller JR, Bressman SB, Eidelberg D. Primary dystonia: is abnormal functional brain architecture linked to genotype? *Ann Neurol*. 2002 Dec;52(6):853-6.

Uluğ AM, Vo A, Argyelan M, Tanabe L, Schiffer WK, Dewey S, Dauer WT, Eidelberg D. Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. *Proc Natl Acad Sci U S A*. 2011 Apr 19;108(16):6638-43.

Valente EM, Edwards MJ, Mir P, DiGiorgio A, Salvi S, Davis M, Russo N, Bozi M, Kim HT, Pennisi G, Quinn N, Dallapiccola B, Bhatia KP. The epsilon-sarcoglycan gene in myoclonic syndromes. *Neurology*. 2005 Feb 22;64(4):737-9.

Vasudevan A, Breakefield XO, Bhide PG. Developmental patterns of torsinA and torsinB expression. *Brain Res*. 2006 Feb 16;1073-1074:139-45.

Vitek JL, Chockkan V, Zhang JY, Kaneoke Y, Evatt M, DeLong MR, Triche S, Mewes K, Hashimoto T, Bakay RA. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. *Ann Neurol*. 1999 Jul;46(1):22-35.

Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, Walker FO. Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor effects of antipsychotic drugs. *Neurology*. 1988 Jun;38(6):961-5.

Walker RH, Brin MF, Sandu D, Gujjari P, Hof PR, Warren Olanow C, Shashidharan P. Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain. *Brain Res*. 2001 May 11;900(2):348-54.

Weinberger M, Hutchison WD, Alavi M, Hodaie M, Lozano AM, Moro E, Dostrovsky JO. Oscillatory activity in the globus pallidus internus: comparison between Parkinson's disease and dystonia. *Clin Neurophysiol*. 2012 Feb;123(2):358-68.

Wichmann T. Commentary: Dopaminergic dysfunction in DYT1 dystonia. *Exp Neurol*. 2008 Aug;212(2):242-6.

Wong DF, Harris JC, Naidu S, Yokoi F, Marenco S, Dannals RF, Ravert HT, Yaster M, Evans A, Rousset O, Bryan RN, Gjedde A, Kuhar MJ, Breese GR. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. *Proc Natl Acad Sci U S A*. 1996 May 28;93(11):5539-43.

Xiao J, Ledoux MS. Caytaxin deficiency causes generalized dystonia in rats. *Brain Res Mol Brain Res*. 2005 Nov 30;141(2):181-92.

Xing J, Andersen RA. Models of the posterior parietal cortex which perform multimodal integration and represent space in several coordinate frames. *J Cogn Neurosci*. 2000 Jul;12(4):601-14.

Zhang L, Yokoi F, Jin YH, DeAndrade MP, Hashimoto K, Standaert DG, Li Y. Altered dendritic morphology of Purkinje cells in Dyt1  $\Delta$ GAG knock-in and purkinje cell-specific Dyt1 conditional knockout mice. *PLoS One*. 2011 Mar 29;6(3):e18357. doi: 10.1371/journal.pone.0018357.

Zhao Y, DeCuyper M, LeDoux MS. Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. *Exp Neurol*. 2008 Apr;210(2):719-30.

Zhao Y, Sharma N, LeDoux MS. The DYT1 carrier state increases energy demand in the olivocerebellar network. *Neuroscience*. 2011 Mar 17;177:183-94.

Zhao Y, Xiao J, Gong S, Clara JA, Ledoux MS. Neural expression of the transcription factor THAP1 during development in rat. *Neuroscience*. 2013 Feb 12;231:282-95.

Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, Müller-Myhsok B, Riedel L, Bauer M, Müller T, Castro M, Meitinger T, Strom TM, Gasser T. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. *Nat Genet*. 2001 Sep;29(1):66-9.



## ACKNOWLEDGMENTS

I am deeply grateful for the extraordinary tutelage I received from Prof. David Eidelberg. As Director of the Center for Neurosciences and Susan & Leonard Feinstein Professor of Neuroscience at The Feinstein Institute for Medical Research, David was highly invested in this line of work. This work would never have been possible without his continued support as well as his input during our controversial and fruitful discussions.

During various periods of this work, I was supported by a Veola Kerr Fellowship of the Parkinson Disease Foundation and by the career development award of the NIH sponsored Dystonia Coalition (U54 NS 065701). Project funds were also provided from the Feinstein Institute for Medical Research, the Bachmann Strauss Foundation, the Dystonia Coalition and the Constance W. and James W. Brown Family Foundation in addition to the NIH sponsoring as indicated in the respective manuscripts.

I also feel indebted to Prof. G. Curio, Prof. M. Endres and Prof. H. Audebert for supporting the submission of my habilitation at the Charité Berlin.

Lastly, I thank my family for all the various forms of practical or emotional support throughout my career.

# Erklärung

§ 4 Abs. 3 (k) der HabOMed  
Habitationsordnung der Medizinischen Fakultät  
Charité - Universitätsmedizin Berlin

Hiermit erkläre ich, dass

1. weder früher noch gleichzeitig ein Habitationsverfahren durchgeführt oder angemeldet wird bzw. wurde,
2. die vorgelegte Habilitationsschrift ohne fremde Hilfe verfasst, die beschriebenen Ergebnisse selbst gewonnen sowie die verwendeten Hilfsmittel, die Zusammenarbeit mit anderen Wissenschaftlern/Wissenschaftlerinnen und mit technischen Hilfskräften sowie die verwendete Literatur vollständig in der Habilitationsschrift angegeben wurden,
3. mir die geltende Habitationsordnung bekannt ist.

.....  
Ort, Datum

.....  
Unterschrift